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Abstract
Effective cancer treatment depends on the development of therapeutics that efficiently
eliminate the disease without significant reduction to quality of life. Targeted ther-
apeutics achieve these goals, but their long-term efficacy is limited by the ability
of cancers to become resistant to these therapies over time. The identification of
new therapeutic targets is crucial for the future of cancer treatment. In this work
we present functional identification and characterization of novel targets for cancer
therapy.
Loss-of-function screens are a well-founded approach for the functional identifica-
tion of new therapeutic targets, and, in combination with high-throughput sequencing
technology, can now be performed at a whole genome scale. However, whole genome
LOF screens often produce unmanageably large data sets from which a few genes are
often arbitrarily selected for further functional studies. We developed a new statisti-
cal analysis and applied it to a focused shRNA library to bridge the gap between a
whole genome LOF study and the identification of promising targets. This approach
revealed a highly promising target gene, DEAD-box helicase 24 (DDX24).
Previously we used a functional screening approach to identify the ζ-1 subunit of
coatomer complex I (COPZ1) as a target that causes cancer-specific cell death. This
subunit is encoded by the COPZ1 gene, which is part of a complex system includ-
ing the homologous gene COPZ2 and intronically encoded microRNAs, miR-148b
(COPZ1 ) and miR-152 (COPZ2 ). To extend the understanding of how inhibition of
COPZ1 causes tumor specific cell death, we probed the cellular signaling pathways
which promote cell death and found that depletion of COPZ1 activates the unfolded
v
protein response (UPR), but ultimately promotes cell death by a UPR-independent
mechanism.
Finally, we used cross-linking, ligation, and sequencing of hybrids (CLASH), a
cutting edge approach to identify direct microRNA targets, to study the microRNA-
148/152 family. MiR-152 has been proposed to play a causal role in the silencing of
the COPZ2 gene and the subsequent efficacy of COPZ1 as a therapeutic target. We
integrated this target dataset with RNA sequencing analysis to identify the functional
target network for the microRNA-148/152 family including genes that computational
target prediction algorithms failed to identify.
This work advances the development of new cancer therapeutics at multiple points
along the therapeutic development pipeline including identification of novel thera-
peutic targets, elucidation of pathways responsible for cancer specific sensitivity to
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1.1 General overview of cancer and targeted therapeutics
Cancer is a genomic disease characterized by altered signaling pathways within the
affected cells [1, 2]. Aberrant changes in signaling pathways begin with genetic mu-
tations which are acquired over an individual’s lifespan or inherited as germline mu-
tations [3, 4]. These genetic mutations result in aberrant RNA expression or protein
sequence causing dysfunction of cellular signaling pathways [5].
Signaling pathways are the mechanisms by which a cell responds to changes in its
internal and external environment [6]. In the most basic sense, signaling pathways
begin with the activation or inactivation of a protein whose function is to “sense”
specific stimuli. While it is easiest to think of signaling pathways as operating under
an “on/off” paradigm, it is important to note that many pathways are under much
more robust controls and have large dynamic ranges of both sensing and signaling
capabilities [7, 8, 9]. The consequence of activating a signaling pathway’s sensor is the
propagation and amplification of a molecular signal from the sensor to the effector
proteins in order to generate a cellular response. The molecular effector proteins
are often transcription factors which activate (or inactivate) the expression of genes
whose products are involved in the cellular process which is required to respond to
the stimuli [6].
In cancer cells, the pathways which are affected by mutations are often involved
in a common set of cellular processes which have been termed the “Hallmarks of
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Cancer” [10, 11]. The first 6 Hallmarks as defined by Drs. Hanahan and Weinberg
were (1) sustained proliferation signaling, (2) evading growth suppressors, (3) ac-
tivating invasion and metastasis, (4) enabling replicative immortality, (5) inducing
angiogenesis, and (6) resisting cell death. To these original hallmarks, they added:
(7) avoiding immune destruction, (8) tumor promoting inflammation, (9) genome in-
stability and mutation, and (10) deregulation of cellular energetics. These Hallmarks
provide physiological advantage to the cancer cells during cancer development.
Adding to the idea that cancer is caused by physiologically advantageous muta-
tions, oncogenic addiction is the ultimate outcome, defined by a cell’s dependence
on these altered signaling pathways [12]. Cancer cells become so dependent on these
aberrant signaling pathways that their disruption results in the cell’s inability to sur-
vive the environment in which it had grown and become dominant. This is the core
concept behind the efficacy of targeted therapeutics [13]. Using small molecules or
other approaches to disrupt signaling pathways to which cancer cells have become
“addicted” causes cancer-specific cell death without affecting normal cells which are
able to compensate through other mechanisms.
However, because cancer cells acquire mutations randomly, every cancer type has
its own specific mutation profile; indeed, the mutation profile between patients with
the same subtype of cancer is unique [14, 15, 16]. Furthermore, each cell within a
patient’s tumor will have its own unique set of mutations which alter its signaling
pathways in unique ways; this is called tumor heterogeneity [17]. The unique mutation
profile and consequent unique set of signaling pathway alterations between and within
tumors makes the treatment of cancer a significant challenge [18]. Not only does
tumor heterogeneity impair the efficacy of targeted therapies, it is one of the primary
mechanisms by which tumors develop resistance to therapy [19, 20, 21].
Tumor heterogeneity and the development of resistance through clonal selection
are major roadblocks on the path to curing cancer. The most promising approach to
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overcoming these barriers is the development of a broad range of targeted therapies
against multiple members of each of the pathways responsible for the hallmarks of
cancer [22, 23, 24]. Therefore identifying new targets and developing an understand-
ing of the role of these targets is of paramount importance to the development of
targeted therapeutics for cancer treatment.
1.2 Application of next-generation sequencing to loss-of-function
studies to identify novel targets for cancer therapy
The efficacy of targeted therapies for cancer treatment is undisputed; however, resis-
tance to targeted therapy is a pervasive problem. The development of new targeted
therapies is needed to overcome this problem. One approach for identifying novel
targets which has proved to be efficacious is loss-of-function (LOF) genetic screening.
LOF screens use inhibitory peptides, RNA, or DNA to artificially simulate the loss
of a gene’s function in cancer. The effect of the lost gene function is then measured
to determine the importance of the that gene product for cancer cell survival, prolif-
eration, or other phenotypic alterations. The most common LOF screening methods
include, GSE screens [25], shRNA screens [26], and more recently sgRNA screens [27].
Screens using these methods provide invaluable information about the role of many
genes in cancer; however, these methods can be costly and time consuming as the list
of interrogated genes becomes larger.
In recent years next-generation sequencing (NGS) technology has become a ma-
jor part of the effort to identify novel therapeutic targets because of its massively
parallel nature and cost effectiveness [28, 29]. The most common NGS platform for
LOF screening applications was developed by Solexa (now Illumina) and uses se-
quencing by synthesis (SBS). This type of sequencing monitors the incorporation of
fluorescently labeled nucleotides into nascent DNA on a flow-cell allowing for millions
of unique DNA sequences to be monitored simultaneously [30]. Using NGS for LOF
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screens requires each element (GSE, shRNA, sgRNA, etc.) to be uniquely identifiable
among a heterogeneous pool of all the elements in the screen. This can be achieved
either through the addition of a unique barcode or sequencing the elements them-
selves (requires each element to be sufficiently unique to identify) [29]. The uniquely
identifiable elements are either stably or transiently transfected into the target cell
line followed by application of some selection procedure in order to select for (or select
against) the transfected element. After selection, the elements are recovered from the
selected cells as well as from a population of non-selected cells. The elements (or their
bar codes) are then sequenced using NGS and the enrichment or depletion of each
element is computed as a ratio of selected versus non-selected. Enrichment or deple-
tion of an element is indicative of its importance in cell survival and growth under
the selection pressure (see Figure 1.1 for basic schema of NGS based LOF screens).
With the application of NGS to LOF studies, researchers are able to generate
pooled libraries of millions of inhibitory elements which target the whole genome
[31]. While these approaches are very powerful, they often lead to a large number
of elements being enriched or depleted. Since the major reason for performing these
studies is to identify targets for therapeutic application, a significant amount of fol-
lowup is required to determine whether an identified target gene is a valuable target.
This presents researchers with the problem of identifying and following up on a very
small subset of the identified potential targets. There is a very real need for an ap-
proach that can leverage the power of NGS to identify and validate the most effective
targets from whole genome screens.
1.3 Validation and delineation of molecular targets
Once a potential therapeutic target has been identified, a significant amount of re-
search must be performed to determine the extent to which targeting the gene of
interest can be effective. That is, due to the heterogeneous nature of cancer, a po-
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tential therapeutic target may only be an efficacious target in a specific type or even
subtype of cancer [32]. Importantly, in-depth studies of identified targets can help
predict mechanisms of resistance as well as possible synergistic drug interactions [33,
34].
Using the NGS based LOF screening approach described above, COPZ1 was iden-
tified as a potential target for cancer therapy [35, 36]. COPZ1 encodes one isoform
of the ζ-COP protein which functions as part of the Coatomer Protein Complex I
(COPI). COPI is responsible for retrograde transport from the Golgi Apparatus to
Endoplasmic Reticulum (ER) and is essential for cell survival [37]. COPZ2 also en-
codes an isoform of the ζ-COP protein. Either isoform of the ζ-COP protein can be
incorporated into the COPI complex to produce a functional complex, but only one
of the isoforms is incorporated at a time [38, 39]. The mechanism of cancer-specific
sensitivity to loss of COPZ1 function is outlined in Figure 1.2 and described in Shtut-
man et al. [35]. Briefly, normal cells express both COPZ1 and COPZ2 and thus loss
of COPZ1 function can be overcome by incorporation of the COPZ2 isoform of the
ζ-COP protein; however, many cancers have silenced the COPZ2 gene which results
in the cancer’s dependence on the COPZ1 gene product for proper COPI function.
To begin to develop COPZ1 as a valid therapeutic target, validation of the efficacy
of COPZ1 depletion in multiple cancer cell lines of different origins is necessary. In
addition, developing an understanding of how cancer cells die as a consequence of
COPZ1 depletion can be highly beneficial for both predicting resistance and identi-
fying synergistic therapeutic combinations.
1.4 MicroRNA-148/152 family: causes and consequences of COPZ2
silencing during cancer progression
miRNAs are small (18-22nt long), non-coding RNAs [40] primarily transcribed by
RNA polymerase II (POLR2A) as independent transcripts or as a portion of a host
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gene (exonic or intronic) [41, 42]. The primary miRNA (pri-miRNA) is processed by
the Drosha enzyme complex in the nucleus to generate a pre-miRNA. Pre-miRNAs
are then exported from the nucleus by Exportin-5. Once in the cytosol, pre-miRNAs
are further processed by Dicer to generate the mature miRNA:miRNA* duplex which
consists of the guide strand (miRNA) and the star strand (miRNA*) [43, 44, 45]. The
miRNA guide strand is preferentially incorporated into the RNA-Induced Silencing
Complex (RISC) [46]. Which strand is the guide and which is the star is determined
by the stability of the 5’ end of the strand [47, 48]. For complete reviews on miRNA
biogenesis and regulation see [49] and [50].
The RISC complex is made up of multiple supporting proteins associated with
the argonaute protein which is the primary mediator of RISC function (AGO2 is
the primary argonaute protein in mammalian cells) [51, 52]. The exact mechanism
by which the RISC complex represses the translation of target mRNAs is still not
completely understood [53], but several key effector proteins and their functions have
been established. In D. melanogaster, the gene GW182 has been shown to be cru-
cial for efficacy of the RISC complex in mRNA translational repression [54]. The
mammalian paralogues of this gene trinucleotide repeat-containing protein (TNRC)
6A, B, and C have been shown to play a role in the recruitment of multiple effec-
tor proteins [55, 56]. Translational repression can be caused by disruption of the
translation machinery, specifically eukaryotic translation initiation factor 4F (eIF4F)
complex [57]. This form of repression is thought to be mediated by poly(A) binding
protein (PABP), which disrupts the interaction of translation initiation factors with
the target mRNA [58]. Destabilization of the target mRNA by the RISC complex is
another mechanism for translational repression. Messenger RNA destabilization can
be caused by 3’-deadenylation which is mediated by the recruitment of the CCR4-
NOT deadenylase complex. Or by 5’-terminal decapping of which is mediated by the
recruitment of DCP1-DCP2 decapping complex and subsequent Xrn1 5’–3’ exonu-
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clease recruitment [56, 59]. The specific roles of each of these effector proteins and
processes has yet to be fully elucidated, but the current consensus is that mRNA
translational repression temporally precedes mRNA destabilization and degradation
[60, 61, 62].
To further complicate the mechanism by which miRNAs repress translation of
their targets, the rules which govern miRNA/mRNA interactions are not completely
understood. The identification of the basic rules of miRNA targeting was one of
the most significant advancements in the field of microRNA research. Briefly, the
canonical rules for miRNA target binding are (i) 2–7bp “seed” sequence binding, (ii)
evolutionary conservation of target site, (iii) target site within the 3’-untranslated
region (3’UTR), and (iv) adenosine anchorage [63, 64]. With these rules firmly es-
tablished, several groups were able to develop bioinformatic algorithms which predict
miRNA-mRNA interactions [64, 65, 66, 67, 68, 69, 70, 71, 72] (see [73] for an ex-
ceptional review of these algorithms). These programs allow researchers to identify
potential targets of their miRNAs of interest before beginning their experimental ap-
proach. These algorithms have lead to a glut of scientific information about many
miRNAs; however, their predictive efficacy is limited by a lack of sensitivity. The fail-
ure to identify differential targets between highly similar miRNAs is a consequence
of incomplete knowledge about how miRNAs interact with their target mRNAs.
Over the past few years, multiple new approaches to miRNA target discovery
have been developed. These approaches consist of capturing the miRNA and target
mRNA within the RISC complex through cross-linking and immunoprecipitation.
Some of the most widely used approaches include high-throughput sequencing of
RNA isolated by crosslinking immunoprecipitation (HITS-CLIP) [74, 75], photoacti-
vatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP)
[76], individual-nucleotide resolution cross-linking and immunoprecipitation (iCLIP)
[77], and cross-linking, ligation, and sequencing of hybrids (CLASH) [78, 79]. HITS-
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CLIP was the first of these approaches which suffered from highly inefficient cross-
linking. PAR-CLIP built on the original HITS-CLIP idea through the addition of
photoreactive 4-thiouridine (4-SU) or 6-thioguanosine (6-SG) in order to maximize
the efficiency of the cross-linking step. Shortly after the development of these meth-
ods, it was discovered that on rare occasions miRNAs would ligate to their targeted
mRNAs resulting in chimeric miRNA/mRNA sequences. Because HITS-CLIP and
PAR-CLIP depended at least partially on target prediction and inference to match
targeting miRNAs with their targeted mRNAs, the identification of chimeric reads
greatly advanced the technique’s power to identify legitimate miRNA/mRNA inter-
actions within the RISC complex. CLASH was developed to increase the efficiency of
chimeric read generation through the addition of a ligation step. CLASH effectively
increases the percentage of miRNA/mRNA chimers from <0.5% to >2%. While
these techniques have vastly altered the approach and scale of miRNA research, their
most important contribution has been to re-write the rule book on miRNA target
prediction through direct detection of miRNA/mRNA interactions within the RISC
complex [78, 80, 81].
The importance of accurate target discovery and identification of legitimate causal
miRNA targets in disease development and progression is an important area of re-
search. The causal role of miRNAs in cancer has been well established [82] and is
a rapidly developing field [83, 84, 85]. In addition, miRNA expression profiles have
been used as prognostic markers for the assessment of patient outcome and also as
biomarkers for disease type and treatment course [86, 87]. These studies point to
the importance of a fuller understanding of miRNA function and regulation both in
normal physiology and in disease states.
While striving to delineate the mechanism underlying the cancer-specific sensitiv-
ity to COPZ1 depletion, it was found that miR-152, a tumor suppressive miRNA, was
intronically encoded within the COPZ2 gene, and furthermore, that miR-148b was
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encoded within the COPZ1 gene [88]. MiR-148b and miR-152 are members of the
microRNA-148/152 family which also includes a third member – miR-148a (Figure
1.3a). It was hypothesized that the silencing of COPZ2 during cancer progression
was driven by the necessity to downregulate the encoded, tumor-suppressive miR-
152 [35]; however, the reason for the specific silencing of miR-152 and it’s host gene
COPZ2 but not the paralogous gene COPZ1 and it’s encoded miR-148b has not been
established. In addition, the function of the microRNA-148/152 family as a whole is
not yet understood. The lack of literature about how the microRNA-148/152 family
members work together (or separately) to alter target gene expression is puzzling
since all three members of the family have identical seed sequences (Figure 1.3b) but
seem to be regulated differently in various cancers (Table 1.1). To address this gap
in knowledge and because we hypothesized that there were unique and consequential
targets that differed between miR-148b and miR-152, we used a modified CLASH
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Figure 1.1: Schema for a standard sequencing based LOF screen. Synthetic loss of
function (LOF) elements are stably transfected into target cells using lentiviral vec-
tors. A portion of infected cells undergo the selection procedure while the remaining
infected cells remain non-selected. After the selection procedure LOF elements are
recovered from both populations and prepared for sequencing. Bioinformatic analy-
sis of the sequencing data results in enrichment and depletion calculations which are






































Normal Cells Cancer Cells
Figure 1.2: Mechanism of cancer specific sensitivity to COPZ1 depletion. Two isoforms of the
ζ-COP protein are produced from the COPZ1 and COPZ2 genes. Either the COPZ1 or COPZ2
gene product can be incorporated into the COPI complex resulting in proper COPI function and
cell survival (left panel). However, cancer cells have silenced the COPZ2 gene which renders them
dependent on COPZ1 for proper COPI function. Loss of COPZ1 in these cells impairs COPI































Figure 1.3: Structure of the miR-148/152 family. (a) The microRNA-148/152 family members are
located on chromosomes 7, 12, and 17. miR-148a is transcribed independently on chromosome 7.
miR-148b and miR-152 are intronically encoded within the COPZ1 and COPZ2 genes located on
chromosomes 12 and 17 respectively. (b) Sequence similarity between microRNA-148/152 family
members. The family members share identical seed sequences (blue) with 2 base nucleotide differ-
ence at positions 9 and 10 (red) and a single nucleotide difference at position 20 (orange). Strong
similarity between these microRNAs makes independent target prediction difficult.
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Table 1.1: Regulation of microRNA-148/152 family across multiple
cancer types
Cancer Type miR-148a miR-148b miR-152 References
Breast D D D [89, 90, 92, 91]
TN Breast D - D [93]
AML D - - [94]
HCC D D D
[95, 96, 97, 98, 99,
100, 101, 102, 103,
104, 105]
Gastric D D D [106, 107, 108, 109,
110, 111, 112, 113]
Colorectal U D D [112, 114, 115, 116,
117]
NSCLC D D - [118, 119, 120, 121,
122, 123]
Osteosarcoma D - D [124, 125, 126, 127]
Bile duct D - D [128]
Prostate D D D [91, 129, 130, 131]
Medulloblastoma U - - [132]
Glioma D - - [133]
GBM U - - [134, 135]
cSCC D - - [136]
CAFs D - - [137]
Pancreatic - D - [138, 139]
Choriocarcinoma - - D [140]
Ovarian - - D [141][92, 142]
Endometrial - - D [143]
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Chapter 2
Identification of novel cancer therapeutic
targets using a designed and pooled shRNA
library screen 1
1David Oliver, Hao Ji, Piaomu Liu, Alexander Gasparian, Ellen Gardiner, Samuel Lee, Adrian
Zenteno, Mengqian Chen, Phillip Buckhaults, Eugenia Broude, Homayoun Valafar, Edsel Peña, and
Michael Shtutman. Submitted to Scientific Reports, 08/11/2016.
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2.1 Abstract
Targeted cancer therapeutics aim to exploit tumor-specific vulnerabilities to iden-
tify genes specifically affecting neoplastic over normal cells. Here we performed deep
sequencing-based screening of an shRNA library on a panel of cancer cells of different
origins as well as normal cells. The shRNA library was designed to target a subset
of genes we previously identified using a whole genome screening approach. This fo-
cused library was infected into cells followed by analysis of enrichment and depletion
of shRNAs over the course of cell proliferation. We developed a bootstrap likelihood
ratio test (BLRT) for the interpretation of the effects of multiple shRNAs over multi-
ple cell line passages. Our analysis identified 44 genes whose depletion preferentially
inhibits the growth of cancer cells. Among these genes ribosomal protein RPL35A,
putative RNA helicase DDX24, and δ-subunit of coatomer complex I (COPI) ARCN1
most significantly affected growth of multiple cancer cell lines without affecting nor-
mal cell growth and survival. Additionally studies showed that the growth inhibition
caused by DDX24 depletion is independent of p53 status underlining its value as drug
target. Overall, our study establishes new approach for the analysis of proliferation-
based shRNA selection strategies and identifies new targets for the development of
cancer therapeutics.
2.2 Introduction
Genetic heterogeneity of human cancers drives the need to develop a broad panel of
therapeutics specifically targeting tumor cells. Therapeutic development depends on
the exploration of genes and pathways critical for the growth and survival of cancer
cells. The most important genes are those whose inhibition ultimately kills tumor
cells while having minimal impact on normal tissues. The most direct approach
for target gene identification is functional profiling with genome wide libraries of
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trans-dominant genetic inhibitors (TGIs). Several types of TGI libraries have been
developed including genetic suppressor element (GSE) libraries [25], small hairpin
RNA (shRNA) libraries [26], and more recently single guide RNA (sgRNA) libraries
[27]. The application of Next-Generation Sequencing (NGS) to the screening of TGI
libraries allows quantitative analysis of screening results [26, 31]. NGS-based screen-
ing procedures are designed to discover genes based on the analysis of enrichment
or depletion of TGIs in cells subjected to selection, relative to non-selected cells.
The major screening strategies for cancer therapeutic target identification are screens
which detect the depletion of growth-suppressing TGIs over the course of cell propa-
gation, or conversely, those which detect the enrichment of growth-suppressing TGIs
[144].
Most previously published functional screens are endpoint procedures [144], where
the abundance of TGIs is analyzed at the initial and final points only. However NGS-
based strategies allow the analysis of multiple data points to determine the kinetics
of shifting TGI abundances. The latter approach, while it provides more informa-
tion about biological processes, is often not used due to the difficulty of analyzing
such complex data sets. Previously we performed BrdU suicide selection of a genome
wide GSE library in a panel of normal and cancer cell lines to select tumor-specific
target genes [35]. The BrdU suicide selection procedure enriches for growth sup-
pressing GSEs. That is, growth suppressing GSEs provide survival advantage during
this selection resulting in their over-representation at the end of the experiment.
Through the initial analysis of this dataset we identified the ζ-subunit of the COPI
complex (COPZ1) [35]. Inhibition of COPZ1 kills a majority of tumor cell lines,
while not affecting the growth of normal cells. Here we re-sequenced and analyzed
this dataset to reveal a large set of potential target genes. To narrow the list we
designed a focused shRNA library against the identified gene set and performed a
proliferation-based selection of the library in four tumor cell lines and normal fibrob-
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lasts. Enrichment or depletion of shRNAs were determined during the course of cell
propagation. The screening results were then analyzed with a BLRT statistical proce-
dure we developed. This screen and analysis procedure revealed a subset of 44 genes
with additional evidence for cancer-specific growth inhibition. The dependence of
cancer cells on these genes was further tested with siRNAs against individual genes.
Three genes successfully showed efficacy in all three selection procedures, ribosomal
protein RPL35A, RNA helicase DDX24, and, in addition to previously identified ζ-
subunit, the δ-subunit of COPI, ARCN1. We show the association of the expression
of the identified genes with development and mortality of human cancers and explore
the mechanism of the effect of ARCN1 and DDX24 depletion in tumor cells.
2.3 Materials and Methods
Cell lines and human tissues
MDA-MB-231, HCT116, HT1080, HeLa, U2OS, DU145, 293FT and PC3 cell lines
were obtained from American Type Culture Collection. HCT116 p53-/- (clone 379.2)
[145] line was a gift of Dr. B. Vogelstein (Johns Hopkins University). BJ normal fore-
skin fibroblasts, immortalized with human telomerase reverse transcriptase (line BJ1-
hTERT) were obtained from Clontech Laboratories. HeLa, U2OS, 293FT, DU145,
MDA-MB-231, HCT116, HCT116 p53-/-, HT1080, and PC3 cell lines were grown in
DMEM with 10% FC2. BJ fibroblasts were maintained in BJ medium (4:1 DMEM/
M199) supplemented with 1 mmol/L of sodium pyruvate and 10% FBS. Flash frozen
tumor and adjacent normal colon tissue samples were obtained from the Center for
Colon Cancer Research Tissue Biorepository at the University of South Carolina
(USC) with oversight and approval from the USC institutional review board . All
samples were consented for use in biomedical research at the time of surgery.
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Genetic suppressor element screen
Construction of the genome-wide GSE library and BrdU suicide selection were de-
scribed previously [35]. To identify genes which were positively selected in this pro-
cedure, CLC workbench was used to map GSEs to the reference genome (hg19 down-
loaded from http://hgdownload.soe.ucsc.edu/goldenPath/hg19/bigZips). Peaks were
called using the CLC workbench ChIP-seq module ( https://www.qiagenbioinform-
atics.com ). The closest gene to a significant (P-value <0.05) peak was identified (if
the peak was not located within a gene then the gene to which the peak was closest
was chosen). The total number of reads in each peak were then normalized to the
library size and enrichment was calculated by the ratio of cancer cell reads to normal
cell reads. Genes with an enrichment greater 1.5 in 2 or more tumor cell lines and/or
targeted with 2 or more GSEs were chosen for further analysis.
Design and construction of focused shRNA library
The focused shRNA library was intended to contain 6 shRNAs against each target
gene such that: (i) each shRNA was 19bp long, (ii) each duplex stability was between
-32 and -28 ∆G, and (iii) each shRNA uniquely targeted the gene of interest (no
other gene had greater homology) using published algorithm [146]. Resulted library
is contained 1273 shRNAs, including 6 shRNA per gene for 209 genes, 5 shRNAs
for one gene, 4 shRNAs for one gene, 3 shRNAs for two genes, 2 shRNAs for two
genes, 1 shRNA for one gene. Each shRNA was assigned error-correcting barcode
sequence, which withstands sequencing errors [147]. See Figure 2.8a for the schema
of the vector. The shRNA and barcode-containing oligonucleotides were synthesized
on-chip (MYcroarray, Ann Arbor MI), 25000 oligonucleotides per chip followed by
droplet PCR amplification with oligo-specific primers. Oligonucleotides mixture was
digested with Bpi I (NEB, Ipswich, MA) and inserted into pRSI9-U6-(sh)-UbiC-
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TagRFP-2A-Puro lentiviral vector (Cellecta, Mountain View, CA). The library DNA
was amplified as described previously [35].
Lentiviral infections
Lentiviral transduction was carried out as described [148] using pCMV-∆8.9 and
pVSV-G packaging constructs. The vector plasmid, pCMV-∆8.9, and pVSV-G DNA
were mixed at 5:4:1 ratio and co-transfected, using the polyethylenimine protocol
[149], into 293FT cells. Lentivirus-containing supernatants were harvested three
times, at 24, 48, and 72 hours after transfection. Lentiviral library infection was
carried out as previously described [31].
Selection of the shRNA library
Recipient cell lines were infected with the shRNA library in duplicates with a MOI
of 0.9. Infected cells were cultivated over a course of five passages. On each passage
one forth of the cells were re-plated and the rest of the cells were used for purification
of genomic DNA. Genomic DNA was purified as previously described [31]. Barcode
sequences were amplified from the DNA with three rounds of PCR (Figure 2.8b),
10 cycles each with the following primer pairs: FwdHTS/RevHTS, FwdGex/Rev-Ind
(1 to 50), and FwGex/Seq2N-AD. The amplified products where purified with PCR
purification kit (Qiagen, Valencia, CA). Unique 8bp indexes assigned to each library
were incorporated in the second round of PCR and Illumina sequencing adapters were
incorporated in the third round of PCR amplification (Figure 2.8b).
Sequencing
50 bp, single end (SE) sequencing was performed at Cornell Epigenomics Core Facility
using Illumina HiSeq2000. Resulting reads consisted of shRNA specific barcodes in
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FASTQ format. FASTQ data were processed in R [150] using an in-house algorithm.
Briefly, reads were split by index to produce FASTQ files containing sequences specific
to a cell line, passage, and biological replicate. Reads were then assigned to a specific
shRNA by identifying the barcode sequence within the read allowing for only a single
mismatch.
siRNA validation
Validation of hits from GSE and shRNA screens was performed using four different
siRNAs from Qiagen (Human genome siRNA Library v1.0) and 4 pooled siRNAs from
GE Healthcare (ON-TARGET plus SMARTpool). siRNA transfection was performed
using reverse transfection method. Briefly, siLentFect (Bio-Rad, Hercules, CA) was
premixed with Opti-MEM media (ThermoFisher Scientific, Waltham, MA) at 0.075ul
siLentFect per 20ul of Opti-MEM according to manufacturer protocol. siRNAs were
added such that the final concentration was 5nM (Qiagen) or 2.5nM (GE Healthcare)
and the siLentFect/Opti-MEM/siRNA mixture was incubated at room temperature
for 20-30 min. Cells were added to premixed siRNA/siLentFect complexes at a seeding
density of 5,000 cells per well in 96 well plate. siRNA treated cells were grown for 5
days at 37oC and 5% CO2.
Cell number quantification
Cell numbers were analyzed using sulforhodamine B (SRB) assay as described [151].
Briefly, plated cells were fixed with 10% TCA at 4oC, followed by washing with water.
Fixed cells were stained with 0.4% SRB solution followed by washing with 1% acetic
acid and drying of the SRB stained cells. SRB was solubilized in 20 mM Tris (pH 10)
and quantified by measuring absorbance of SRB solution at 540 nm minus absorbance
at 630 nm (background absorbance).
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Colony formation assay
siRNA-transfected cells were plated at 2,500 cells per well in 6 well plate followed
by cultivation 10 days. Colonies were fixed and stained with crystal violet fixing
Solution (0.25% Crystal Violet, 3.7% formaldehyde, 10% H2O, 80% methanol) as
described [152]. Stained plates were imaged with ChemiDoc Touch Imaging System
(Bio-Rad) and resulting images were quantified using the Colony Area Plugin [153]
for ImageJ [154].
Western blot
To prepare total protein extracts for Western blot analysis, cells (3x10E5 - 10E6 per
sample) were lysed according to standard procedure in TNT lysis buffer (20 mM Tris
HCl, pH 7.5, 200 mM NaCl, 5 mM EDTA, 1% Triton X-100), supplemented with 1mM
DTT and Pierce Protease Inhibitor cocktail (Thermo Scientific, Cat. No. 88266). To-
tal protein extracts from flash frozen tissue (5 mg per sample) were crushed in followed
by homogenization in TNT buffer. Protein concentration was measured using Pierce
BCA protein assay kit (Thermo Scientific, Cat. No. 23227) according to the manu-
facturer’s protocol. Protein expression (20 ug per sample) was analyzed by Western
Blotting with primary antibodies: p53 (DO-1, BD Biosciences, Cat. No. 554293), p21
(H-164, Santa Cruz Biotechnology, Cat. No. sc-756), DDX24 (Bethyl Laboratories,
Cat. No. A300-698A-T), ARCN1 (GeneTex, Cat. No. 103252) GAPDH (Santa Cruz
Biotechnology, sc-32233) and β-Actin (Thermo Scientific, Cat. No. MA5-15739),
and corresponding (HRP)-conjugated secondary antibodies (Thermo Scientific, Cat.
Nos. 31460, 31430) The images were obtained using ChemiDoc Touch Imaging Sys-




Cells cultured on glass coverslips (Bellco Glass) were fixed with 3.7% paraformalde-
hyde and permeabilized with 0.5% Triton X-100. The coverslips were blocked with
3% (BSA) incubated with mouse anti-GM130 primary antibody (BD Biosciences,
610822) and DAPI (Invitrogen). The Secondary antibody was Cy3-conjugated goat
anti-mouse IgG (Jackson, 711-165-152). Fluorescence images were acquired with a
PlanApo/N 60/1.42 NA objective on an Olympus IX81 microscope. Hamamatsu
C10600 camera gain and exposure time settings were controlled with Metamorph Ba-
sic. Processing of images (merging, brightness, and final size) was performed using
Fiji software [155, 154].
Gene ontology
Gene ontology analysis was performed using the Gene Ontology Consortium website’s
enrichment analysis tool [156, 157] or Kegg Mapper Pathways tool [158].
Association of gene expression with survival of cancer patients
Association of expression of the genes in GEO deposited Affymetrix data sets with
relapse-free survival of breast cancer patients, progression free survival of ovarian can-
cer patients, and overall survival of gastric and lung cancer patients was determined
using KM-plotter online survival analysis tool (http://kmplot.com/analysis/) with
“Auto select best cutoff” option [159, 160, 161, 162].
Statistical analysis of siRNAs screening results
For siRNA toxicity, we used six biological replicates and performed two sided Welch’s
t-tests with Holm-Sidak correction for multiple testing when necessary. T-tests and
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multiple testing corrections were performed with GraphPad Prism (GraphPad Soft-
ware, La Jolla CA).
Bootstrap LRT to test regression coefficients lying in a cone (shRNA
screening analysis)
shRNAs of interest were measured in both normal and cancerous cell lines at dif-
ferent passages. Assuming shRNA measurements are independent and identically
distributed normal random variables, a simple linear regression (SLR) is performed
to estimate the rate of change in the mean shRNA reads over multiple passages for
each type of cell populations. Let Ŷ1 and Ŷ2 denote the estimated mean normalized
shRNA reads for the cancer and normal cell lines, respectively. Let X1 and X2 de-
note the covariate vectors that indicate passage number for the measurements in the
experiment. Let n1 and n2 denote the number of unique shRNAs targeting a gene in
cancer and normal cell lines respectively. For i = 1, 2, · · · , n1, and j = 1, 2, · · · , n2,
the fitted values of the shRNA reads are
























(Y2j − Ȳ2j)(X2j − X̄2j)
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The goal of the study is to test whether the (β11, β21)-pair lies within the region
of interest, which is the region of [3π4 ,
5π
4 ] on a 2D plane formed by using β11 as the
x-axis, and β21 as the y-axis. A bootstrap likelihood ratio test (BLRT) is constructed
to compare slopes of the two regression lines in equation (2.1). We assume equal
variances in both normal and cancerous shRNA measurements, denoted by σ2. σ2, β10
and β20 are then considered as nuisance parameters in this BLRT and we can form
the following hypothesis:
H0 : {|β21| > |β11|, β11 < 0} ∪ {β11 > 0} Ha : |β21| ≤ |β11|, β11 < 0 (2.4)
That is, under the null hypothesis the absolute value of the slope of the regression
for the normal cell line (|β21|) is more extreme than the absolute value of the slope of
the regression for the cancer cell line (|β11|) when the slope of the cancer cell line is
less than 0 or the slope of the line for cancer cells is greater than 0 (indicating that the
shRNA is more effective at reducing the survival/proliferation of normal cells than
cancer cells or is ineffective at reducing the survival/proliferation of cancer cells).
Under the alternative hypothesis the absolute value of the slope of the regression
for the normal cell line is less extreme than the absolute value of the slope of the
regression for the cancer cell line when the cancer cell line slope is less than 0.
Let Θr denote the restricted parameter space,
Θr = {(σ2, β10, β11, β20, β21) : σ2 ≥ 0, |β21| ≤ |β11|, β11 < 0, β10, β20 ∈ R}
Let Θ denote the unrestricted parameter space,
Θ = {(σ2, β10, β11, β20, β21) : σ2 ≥ 0, β11, β21, β10, β20 ∈ R}
The likelihood ratio λ(Y1,Y2) is then the likelihood of the null model over the
























In equation (2.1) and (2.2), we obtain unrestricted parameter estimators for the
regression equations. The restricted estimators are obtained by maximizing the like-
lihood of the data over the restricted parameter space Θr. The estimators are shown
below
1. When the unrestricted Maximum Likelihood Estimates (MLEs) for β11 and β21
fall in the [3π4 , π] region, then the restricted MLEs of β11 and β21 satisfy the
property that β̂r21 = −β̂r11, that is, they reside on the upper boundary of the


























2. When the unrestricted MLEs for β11 and β21 fall in the [π, 5π4 ] region, then the
restricted MLEs of β11 and β21 satisfy the property that β̂r21 = β̂r11, that is,
they reside on the lower boundary of the region of Θr. As such the restricted


























We then derive the negative log of the LRT statistic using equation (2.5)




where σ̂2r is the estimated variance under the null and σ̂2 is the estimated unre-







[Y1i − (β̂r10 + β̂r11X1i)]2 +
n2∑
j=1







[Y1i − (β̂10 + β̂11X1i)]2 +
n2∑
j=1
[Y2j − (β̂20 + β̂21X2j)]2

Denote the value of the test statistic from a observed data sample T0. To ob-
tain a P-value for the LRT, T0, we approximate the null sampling distribution of
the likelihood ratio test statistic via bootstrapping. We do this via the following
procedure:
1. Obtain SLR residuals e1i, i = 1, 2, · · · , n1 and e2j, j = 1, 2, · · · , n2 for both
the normal and cancerous cell lines in the sample. e1i = Y1i − (β̂10 + β̂11X1i);
e2j = Y2j−(β̂20 + β̂20X2j), where β̂11, β̂10, β̂20, β̂21 are the unrestricted maximum
likelihood estimates (MLE) of the regression parameters.
2. Combine vector e1 = (e11, e12, · · · , e1n1) and e2 = (e21, e22, · · · , e2n2). So, the
combined vector is e = (e1, e2).
3. Obtain two samples of bootstrap residuals of size n1 and n2 from e. Call the
two samples of residuals S1 and S2. S1 and S2 each is a random sample from e.
4. Using restricted estimates, create a bootstrap sample (Y∗1,Y∗2) by adding
non-restricted residuals in step 1. For example, for i = 1, 2, · · · , n1,S1 =
(s11, s12, · · · , s1n1),
Y ∗1i = β̂r10 + β̂r11X1i + s1i (2.7)
5. Compute the test statistic as in equation (2.6), say T ∗i for sample (Y∗1,Y∗2)
using the proposed negative log of the LRT.
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6. Repeat steps 1-5, and compute a large number, say M = 1000, such test statis-
tics.






. This p-value is used
to test the H0 vs the H1.
This analysis was performed in R [150], using the MASS[163], reshape2 [164], and
preprocessCore [165] packages. The code for the statistical analysis presented here is
available for download at
https://github.com/doliv071/Focused_shRNA_Analysis.git
2.4 Results
Genetic suppressor element library screen
Previously we constructed a library of GSEs composed of cDNA fragments from the
human transcriptome (average length 135 bp) prepared from a mixture of normalized
(reduced-redundancy) cDNAs from 18 cell lines derived from different types of cancers
[35]. The library was subjected to BrdU-suicide selection (Figure 2.7a) for identifi-
cation of growth suppressing GSEs in three tumor cell lines: MDA-MB-231 (breast
cancer), PC3 (prostate cancer), and HT1080 (fibrosarcoma), as well as immortalized
normal human foreskin fibroblasts, BJ-hTERT. The cDNA fragments were recovered
and amplified from genomic DNA of BrdU selected and non-selected cells [35]. We
performed additional sequencing of the library by 454 sequencing (Roche), obtain-
ing approximately 100,000 GSE reads per sample. Target genes were identified by
mapping fragments back to the human genome. 221 genes were targeted by GSEs
enriched more than 1.5 fold in two or three tumor cell lines relative to normal cells.
Gene Ontology based functional analysis showed that the set was enriched for genes
involved in RNA splicing (18 genes) and translation (21 genes). Also, eight genes
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involved in the PI3K-AKT signaling pathway were identified using KEGG pathways
analysis.
Design, construction, and screening of focused shRNA library to
select growth inhibitory shRNAs
To analyze the cancer cell-specific efficacy of inhibiting the 221 genes identified in the
GSE screen, we designed a focused shRNA library. The main goal of the selection
was to identify shRNAs depleted in proliferating tumor cell lines relative to normal
fibroblasts. The shRNA library was designed to have six unique shRNAs against
each of the 216 genes identified in the GSE data set (6 unique shRNAs could not be
designed for 5 of the identified genes. See Materials and Methods for details). Each
shRNA was tagged with a unique barcode and an amplification adapter for rapid
identification of unique shRNAs within the pool (Figure 2.8a,b). The shRNAs and
barcodes were synthesized on-chip by parallel nucleotide synthesis, and subsequently
inserted into the lentiviral vector.
Normal fibroblasts (BJ-hTERT), breast cancer (MDA-MB-231), colon cancer
(HCT116), prostate cancer (PC3), and fibrosarcoma (HT1080) cell lines were in-
fected with library-containing lentiviruses in duplicates. The library-infected cells
were passaged five times to undergo approximately 20 divisions (Figure 2.1a). At
each passage (approximately every fourth division) genomic DNA was isolated from
a portion of the cells and the barcode-containing sequences were PCR amplified from
the genomic DNA. During the second round of amplification, indexes were added to
each library for multiplexing of the resulting libraries (Figure 2.8b). The resulting
50 libraries were pooled and sequenced with an average 3 million reads per sample.
Sequenced samples were split by index and unique shRNA barcodes were counted
using a bespoke algorithm. Barcode read data were then used to analyze enrichment
and depletion of shRNAs over passages (Figure 2.1b). The amplification and index-
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splitting procedure we developed allows for the parallel sequencing of as many pooled
libraries as needed (far more than 24 pooled libraries allowed by standard procedure
of Illumina).
Development of a bootstrapped likelihood ratio test procedure to
identify genes of interest
In order to analyze this dataset we developed a modified general linear model ap-
proach using normalized shRNA reads as the response variable and passages as a
predictor (Figure 2.2a,e(i)). We defined a region of interest where the slope of the
fitted line for the six shRNAs against a gene in the cancer cell line being queried is
less than zero while the corresponding slope for the shRNAs against the same gene in
the normal cell line is not more extreme than the cancer cell line (Figure 2.2b,e(ii)).
This criterion allows for flexible normal cell line response to the shRNAs targeting
the gene of interest while constraining the cancer cell line to depletion of the same
shRNAs over passages. Specifically, shRNA barcode reads were normalized using
upper-quantile normalization followed by Box-Cox transformation (λ ≈ 0.5). Since
we used a general linear model, we checked that the normality assumptions were met
before modeling (Figure 2.9). Once the model was fitted, we identified genes whose
shRNAs affected cell growth such that the slope of the shRNA reads as a function
of passage fell within the region of interest described above (Figure 2.2a,b). If the
estimated slopes were found to be within the region of interest, then we calculated
the likelihood ratio test (LRT) statistic for that gene (Figure 2.2c,e(iii)). To cal-
culate a P-value for the gene-specific LRT statistic, we performed bootstrapping by
re-sampling the residuals 10,000 times, calculated LRT for each bootstrapped sample
to determine the probability of observing a LRT statistic at least as extreme as the
observed LRT statistic value (Figure 2.2d,e(iv)); Methods: Bootstrap LRT to test
regression coefficients lying in a cone).
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Identification of shRNAs that inhibited the growth of tumor cells
For the first three passages, the variability between the biological replicates was small
and the correlations were strong. After passage 3, there was variability between the
biological replicates that prevented any genes from passing our threshold for statistical
significance (p <0.05) after multiple testing corrections. However, 72 genes had some
evidence for selective targeting (-2ln(LRT) >0) in the cancer cells compared to the
normal control cell line through 5 passages. We stratified these genes by evidence in
the four cancer cell lines. Genes in group 1 had evidence had a -2ln(LRT) >0 in all
four cell lines. Genes in group 2 had a -2ln(LRT) >0 in 3 cell lines. Genes in group
3 had a -2ln(LRT) >0 in 2 cell lines. For the last group (group 4), since the evidence
is only in a single cell line, the requirements were made more stringent, by requiring
the LRT statistic to be greater than 0.1. Of the original 72, 44 genes fell into at least
one of these four categories. 26 of the 44 genes have been previously reported to be
involved in cancer. Of the 6 genes in group 1, 4 were identified previously as having a
role in cancer. Of the 9 genes in group 2, 5 have been previously identified as cancer
related genes. 19 genes were identified in group 3, of which 12 have been previously
reported to have an involvement in cancer. Finally, 10 genes were identified in group
4, 5 of which have been previously reported to be involved in cancer. The fact that
many of these genes had been previously identified as having a role in cancer supports
the validity of our method to identify potential cancer therapeutic targets.
Secondary siRNA screens identify potential therapeutic targets
The genes identified in the focused shRNA screen were subjected to further analysis
to reveal whether short-term depletion of the gene would provide a similarly discrimi-
natory effect (between tumor and normal cells) observed with the significantly longer
shRNA treatment. To this end, the effects of siRNA knockdown of the 44 selected
30
genes were assessed in HCT-116, MDA-MB-231, PC-3, and BJ-hTERT cells. The
cells were transfected with pooled siRNAs (GE Healthcare) in 96 well format, fol-
lowed by quantification of the cell number five days after transfection. The siRNA
depletion of 3 genes - ARCN1, DDX24, and RPL35A - significantly inhibited the
growth of all three cancer cell lines but not normal cells. The growth inhibitory ef-
fects of pooled siRNAs were confirmed by the depletion of the genes with different
individual siRNAs from another source (Qiagen) (Figures 2.3a and b, 2.4a, 2.5a).
Depletion of RPL35A preferentially inhibits growth of tumor cells
and its expression correlates with poor survival of cancer patients
RPL35A is a part of the large ribosomal subunit. The depletion of RPL35A with
pooled siRNAs as well as with four individual siRNA preferentially inhibited growth
of tumor cell lines (Figure 2.3a,b). Conversely, analysis of gene expression profiles
deposited in GEO shows that high expression level of RPL35A strongly correlated
with poor survival of breast, ovarian and lung cancer patients (Figure 2.3c).
Effects of ARCN1 depletion on growth and Golgi integrity
The ARCN1 gene encodes the δ-COP protein which is an integral component of the
COPI complex [166, 167]. Previously we showed that depletion of another subunit of
the COPI complex, ζ1-COP protein, caused Golgi disruption followed by cell death
in the majority of tumor cell lines but not in normal cells [35]. To compare the mech-
anisms of selective growth inhibition of tumor cells we analyzed the results of δ-COP
depletion in MDA-MB-231 breast carcinoma cells and BJ-hTERT fibroblasts (Figure
2.4b). Contrary to the results obtained from ζ1-COP depletion, δ-COP siRNAs in-
duced Golgi disruption in both MDA-MB-231 and immortalized fibroblasts (Figure
2.4c), while affecting the growth of cancer cells only (Figure 2.4a). Furthermore, the
analysis of ARCN1 expression in human tumors shows, that high level of ARCN1
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expression correlates with lower survival rate of gastric, ovarian, and HER+ positive
breast cancer patients (Figure 2.4d).
Depletion of DDX24 inhibits growth of tumor cells regardless of
p53 status
DDX24 is a member of the DEAD-box family of putative RNA helicases [168] which
have been implicated in diverse cellular functions [169, 170, 171, 172, 173, 174].
However, to our knowledge, this is the first identification of DDX24 as a target for
selective inhibition of tumor growth (Figure 2.5a). Our initial results showed that
depletion of DDX24 inhibits the growth of tumor cells with a variety of p53 sta-
tuses, including HCT116 with a normal level of the wild-type p53, MDA-MB-231
with mutated p53, and PC3 which are p53 null [175] (Figure 2.5a). Furthermore,
siRNA-mediated DDX24 depletion in parental (p53+/+) and p53-/- HCT116 cells
also inhibits the growth of both wild type and p53-/- cells with similar efficacy (Figure
2.5b), while elevating p53 and p21 expression in p53 +/+ cells but not p53-/- cells
(Figure 2.5c). Similar results were observed with DU145 cells expressing p53-223Leu
and p53-274Phe mutant proteins [175] (Figure 2.5d). DDX24 knockdown induces p21
expression in BJ-hTERT normal fibroblasts (Figure 2.5d) without significant effect
on cell growth (Figure 2.5a).
The level of DDX24 protein is elevated in all but one tumor cell lines we tested
relative to BJ-hTERT fibroblasts (Figure 2.6a). Moreover, DDX24 protein expression
is significantly upregulated in two out of four samples of colon cancer tissues relative to
normal counterparts (Figure 2.6b). Analysis of expression of DDX24 in human tumors
suggested that high level of the gene expression correlates with a lower survival rate
of Gastric and HER2+ positive breast cancer patients (Figure 2.6c). Furthermore,
the level of DDX24 expression is elevated in cervical cancers tissues and cell lines,
relative to normal tissues (Figure 2.6d).
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2.5 Discussion
We have developed a screening and analytical discovery protocol to identify novel
genes required for growth and survival of tumor cells but not normal cells. The
procedure employs (i) screening of a full genome GSE library, (ii) validation of the
selection results with a designed shRNA library, and (iii) additional validation with
gene-specific siRNAs. All screens were performed on a panel of tumor cell lines of dif-
ferent origin (prostate, breast, colon, and connective tissues) and normal fibroblasts.
The negative selection pressure against elements of the focused shRNA library was
ascertained through NGS-based monitoring of shRNA-specific reads over the course
of multiple passages. To statistically analyze the effects of several shRNAs (6 per
gene) over 5 passages per cell line in biological replicates, we developed a procedure
utilizing a linear regression approach. During the development of this paper, an alter-
native approach that adapts the edgeR software [176] for differential gene expression
analysis to perform this type of analysis was implemented [177].
Re-sequencing and analysis of the GSE selection we did previously [35] identified
221 genes targeted by growth inhibitory GSEs. Genes were selected for follow-up if
their GSEs were enriched more than 1.5 fold in two or more tumor cell lines but not in
normal fibroblasts. Follow-up validation with a focused shRNA library confirmed 44
genes; 26 of these had been previously linked to cancer development and progression.
The selective dependency of tumor cells on the expression of the genes was further
tested with siRNAs. The experimental procedure for siRNA-based analysis consisted
of a short, 5-day treatment which was strikingly different than the shRNA library
selection (5 passages over 16 to 25 days). It is therefore not surprising that depletion of
only three genes, ribosomal protein RPL35A, δ-subunit of the COPI complex ARCN1,
and RNA helicase DDX24 selectively inhibited the growth of all three cancer cell lines
without strong effects on BJ-hTERT cells.
The RPL35A gene encodes a 110 aa protein which functions as a part of the
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large ribosomal subunit. Previous studies have shown that mutations in the RPL35A
gene are associated with Diamond-Blackfan anemia [178]. Interestingly, Farrar et al.
used TF-1 and UT-7 leukemic cell lines to model the effects of RPL35A mutations.
They demonstrated that RPL35A is essential for proper growth and proliferation of
these cells [178]. Furthermore, Lopez et al. found that RPL35A over-expression in
Jurkat cells (an acute T-cell leukemia derived cell line) produced a cell death resistant
phenotype [179] without producing concomitant changes in the expression levels of
Bcl-2 or Bcl-xL, suggesting a more complex mechanism for resistance than apoptotic
signaling alterations. These results combined with our identification of RPL35A as
a potent growth inhibitor in 3 additional cancer cell lines suggest that RPL35A is
a key factor for survival of cancer cells, while it is less important for normal cell
homeostasis.
ARCN1 encodes the δ-subunit of the COPI complex. The complex is required for
retrograde Golgi to ER traffic, Golgi stack maintenance, and autophagy [36]. The
analysis of ARCN1 expression in human cancers revealed the association of the high
level of gene expression with poor survival of gastric cancer patients and patients with
HER2-positive breast cancer. Previously we identify COPI complex as a prominent
target for cancer therapy [35]. Depletion of COPZ1 encoding ζ-subunit of COPI
complex kills the majority of tumor cell line we tested causing the Golgi to collapse
and subsequently inducing apoptosis. In comparison, ARCN1 depletion caused loss of
Golgi integrity in both tumor and normal cells , which suggested that the mechanism
of differential sensitivity of tumor cells to ARCN1 depletion is different from that of
COPZ1 depletion and yet to be identified. Overall the results confirmed our previous
finding of the COPI complex as a target for cancer therapy. It is further supported
by the recent publication by Kim et al. who also identified ARCN1 as a potential
target for the selective growth inhibition of non-small cell lung cancer cells [180].
DDX24 is the most promising target we identified due to potential druggability
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of the DDX24 protein. DDX24 belongs to the large group of DEAD-box RNA heli-
cases, some of which have been previously identified as potential targets for cancer
therapy. Several small molecule inhibitors of DEAD-box RNA helicases have been
developed [181]. DDX24 is involved in multiple biological processes including HIV-1
infection [169, 182], interferon signaling [171, 172], and rRNA processing [170, 183].
Importantly, DDX24 interacts with MDM2, p300, and p53 [170, 173, 174, 184, 185].
Our results along with another recent report [174] show that depletion of DDX24
activates p21 expression in a p53 dependent manner. However, siRNA depletion of
DDX24 equally inhibits the growth of both p53 positive and p53 negative tumor cell
lines. The mechanisms of growth inhibition by DDX24 depletion have yet to be iden-
tified and may involve defects in ribosomal RNA biogenesis [183, 170]. In line with
our results, inhibition of ribosomal biogenesis induces elevation of the p53 protein
[186]. Analysis of publicly available expression profiles of human tumors showed that
high level of DDX24 expression correlates with decreased survival of HER2 positive
breast cancer and gastric cancer patients. Moreover, significant elevation of the level
of DDX24 protein was detected in the majority of tumor cell lines of different origin
and in 50% of colon cancer tissues we tested. The results are further confirmed by
recent results which show the elevation of DDX24 expression in many breast cancer
cell lines [174]. Taken together these results suggest DDX24 as a promising target for
the development of therapy for a variety of tumors.
To conclude, our results show that the approach described above identifies genes
necessary for cancer cell survival, and the identified genes are promising targets for
further development of cancer therapeutics.
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Figure 2.1: Experimental design of focused shRNA library screen and sequencing. (a) The focused
shRNA library was infected into BJ-hTERT, PC3, MDA-MB-231, HCT116, and HT1080 cells. 48
hours later cells were collected. One forth of the cells were re-plated (P1) and the rest were used
for genomic DNA extraction. The procedure was repeated for 4 passages (P2-P5). During the
3-step barcode amplification (See Materials and Methods for details) unique index-sequences were
added to amplified fragments from each sample. Resulting indexed libraries were mixed together
and subjected to Illumina sequences. (b) Sequencing data were processed first by identifying the
sample index and then by identifying the specific shRNA barcode resulting in cell line, passage
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Figure 2.2: Statistical analysis of shRNA depletion over multiple passages. (a) A representation
of the linear regression model calculated for all shRNAs targeting a single gene over five cell line
passages for cancer (red) and normal (blue) cells. (b) The region of interest (demarcated in red) is
defined by depletion of shRNA reads in cancer cell lines and less extreme depletion or enrichment
in normal cells. (c) The likelihood ratio test statistic for genes within the region of interest is
the -2ln of the likelihood of the regression parameters being located outside the region of interest
(null model) over the likelihood that the regression parameters are within the region of interest
(alternative model). (d) A p-value for the observed likelihood ratio statistic, for a given target
gene, is calculated as the probability of observing a value at least as large as the observed value out
of 10,000 residual re-sampling bootstraps. (e) The analysis of shRNA reads over multiple passages
is performed by (i) calculating the linear regression model for the cancer cell line of interest and
the normal cell line. (ii) shRNAs whose regression parameters fall within the region of interest are
then identified. (iii) The likelihood ratio test statistic is calculated for shRNAs within the region





Figure 2.3: RPL35A depletion significantly reduces cancer cell growth compared to normal cells.
(a) BJ-hTERT and HCT116 cells were transfected with four individual siRNAs, 5nM each (Qiagen).
The number of cells was quantified 5 days after transfection using sulforhodamine B assay. Bars
represent mean normalized absorbance at 540nm +/- 1 SD (P-values: 0.0035, 7.6356e-05, 0.0009,
N.S.). P-values were calculated using single tailed Welch’s t-test. (b) BJ-hTERT, HCT116, MDA-
MB-231, and PC-3 cell lines were transfected with 2.5nM of pooled siRNAs (GE Healthcare). Cell
number determined and represented as in (a)(P-values: all <0.0001). Significance calculated as
above but with additional Holm-Sidak correction for multiple testing. (c) Association of RPL35A
expression in Affymetrix array datasets with survival of ovarian, breast, and lung cancer patients
was analyzed using KM-plotter [159]. Plots represents survival of patients with high (red) and low
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Figure 2.4: ARCN1 is a potential target for cancer therapy. (a) BJ-hTERT and HCT-116 were
transfected with 5nM individual siRNA (Qiagen) (Upper Panel). BJ-hTERT, MDA-MB-231, HCT-
116, and PC3 cells were transfected with 2.5nM of pooled siRNAs (GE Healthcare) (Lower Panel).
Cell number, representation, and statistical tests were done as in Figure 3. P-values are <0.0063
and All <0.0001 for Upper and Lower Panels respectively. (b) ARCN1 and COPZ1 expression
were analyzed by WB in MDA-MB-231 and BJ-hTERT cells. Cells were transfected with control,
ARCN1, or COPZ1 siRNAs (2.5nM, GE Healthcare pooled siRNAs). Cells were lysed 72h post-
transfection followed by WB analysis of β-Actin, ARCN1, or COPZ1 proteins with corresponding
antibodies. (c) BJ-hTERT and MDA-MB-231 cells were transfected with COPZ1, ARCN1, and
control siRNA (as in b). Golgi and cell nuclei were visualized by IF with anti-GM130 and DAPI.
Depletion of ARCN1 results in Golgi disruption (no distinct tubular structure) in both normal (BJ-
hTERT) and cancer cells (MDA-MB-231), while depletion of COPZ1 by siRNA results in selective
disruption of the Golgi in cancer cells without affecting the Golgi in normal cells. (d) Association of
ARCN1 expression with survival of gastric, breast, and ovarian cancer patients. KaplanâĂŞMeier


























































































Figure 2.5: DDX24 mediated inhibition of cancer cell growth is independent of p53. (a) BJ-hTERT,
HCT116, MDA-MB-231, and PC-3 cell lines were transfected with 2.5 nM pooled DDX24 siRNAs
(GE Healthcare). Cell number, representation, and statistical tests as in Figure 3 (P-values: 0.0026,
0.0004, and 0.0002, respectively). (b) HCT-116 with p53 wild-type (p53+/+) and p53 null (p53-/-)
were transfected with 5nM of control or DDX24 siRNAs and subjected to colony formation assay.
Cells were transfected in triplicate and plated at 1,000 cells per well followed by quantification of
total colony area. Bars represent average +/- 1 SD (P-values: 0.0005 and <0.0001, respectively). (c)
WB analysis of p53, p21, and DDX24 expression in wild-type HCT-116 and p53-/- cells. Cells were
transfected with 5nM of siRNAs and lysed 72h post-transfection followed by WB with corresponding
antibodies. (d) WB analysis of p21 and DDX24 expression in DU145 and BJ-hTERT cells. Cells
were transfected with 5 nM of pooled siRNAs and lysed 72h post-transfection following by WB
with corresponding antibodies.
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Figure 2.6: DDX24 expression is up-regulated in cancer and correlates with survival. (a) Western
blot analysis of DDX24 expression in BJ-hTERT, HeLa, HT1080, MDA-MB-231, DU145, HCT116,
U2OS, and PC3 cell lines. Bars represent normalized DDX24/GAPDH intensity. (b) Western blot
analysis of DDX24 expression in 4 pairs of matched tumor and normal colon tissue. Bars represent
normalized DDX24/GAPDH intensity (c) Association of DDX24 expression with survival of gastric
and HER positive breast cancer patients. The Kaplan-Meier analysis performed as described in
Figure 2.3. (d) The Expression level of DDX24 in cervical cancer cell lines, primary tumors, and
benign tissues [187] (microarray data deposited in GEO database). P-values, generated using single
tailed Welch’s t-test with Holm-Sidak correction for multiple testing, are indicated for significant
differences between the groups.
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Gene Infected Selected Enrichment
Gene U 59 30 0.51
Gene V 69 26 0.38
Gene W 55 42 0.76
Gene X 33 75 2.27
Gene Z 25 40 1.60
Selected for shRNA Screen
Gene X Gene Z
Infected
Gene X Gene Z
Gene X Gene Z
Selected






























Figure 2.7: Genetic Suppressor Element selection procedure. (a) Genetic suppressor element-
containing, Doxycycline-inducible vectors are infected into a panel of normal and cancer cell lines.
GSE-vector expression is induced by Doxycycline (DOX) treatment and then submitted to BrdU
suicide selection for 72 hrs. BrdU-containing DNA is cross-linked with the addition of Hoechst
33342 and white light. DOX and BrdU are then removed to allow cells to recover. Finally, GSEs
are recovered from genomic DNA through PCR amplification and sequencing. (b) Recovered GSEs
from infected (no selection) and selected cells are aligned to the reference genome and peaks are
called with CLC Workbench (Qiagen). Peaks are assigned to the nearest gene and reads per gene





Figure 2.8: shRNA library design and recovery. (a) Designed shRNA oligonucleotides containing
vector adapters, shRNA hairpin, sequencing primer, and shRNA-specific barcode are incorporated
into a lentiviral vectors and amplified before being applied to 293FT cells for viral production. (b)
After viral library selection (Figure 2.1), shRNA-specific barcodes are recovered from selected cells
through 3-step PCR amplification. The resulting barcodes are then indexed with custom indexes






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Theoretical Quantiles Theoretical Quantiles Theoretical Quantiles Theoretical Quantiles Theoretical Quantiles
Figure 2.9: Validation of normality assumption for linear modeling. Quantile-quantile plots showing
normality of shRNA reads after normalization. Each panel corresponds to a cell line, passage
number (1-5), and biological replicate (A or B).
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Figure 2.10: Correlation of shRNA reads across replicates and passages. Each panel displays
the correlation matrix across replicates and passages for each cell line. The lower triangle
in each panel shows the scatter plot of shRNA reads. The upper triangle contains the
correlation coefficient for the corresponding passage and replicate.
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Chapter 3
The mechanism of cancer specific cell death
induced by COPZ1 depletion1




The coatomer protein complex 1 (COPI) is responsible for retrograde transport from
the Golgi apparatus to the Endoplasmic Reticulum (ER) and maintenance of the
Golgi structure. We previously identified COPZ1, a subunit of the COPI complex, as
a potential therapeutic target for the treatment of cancer and reported the mechanism
by which cancer cells are selectively sensitive to COPZ1 depletion. Here we build on
our previous findings in order to better understand the mechanism by which cancer
cells undergo apoptotic cell death. Understanding the specific signaling pathways
responsible for apoptotic cell death caused by targeted therapeutics is an important
question for identifying mechanisms of resistance and potential synergistic drug com-
binations. In this study we show that siRNA depletion of COPZ1 causes apoptotic
cell death in multiple cancer cell lines of different origins. Furthermore, COPZ1 deple-
tion causes Golgi collapse and ER stress-mediated activation of the unfolded protein
response (UPR). Through inhibition of individual components of the UPR and block-
ade of all UPR signaling we show that the UPR is not the primary mechanism for
cell death signaling caused by COPZ1 depletion. These findings open up new lines of
inquiry regarding the signaling mechanism responsible for apoptosis during COPZ1
depletion.
3.2 Introduction
Targeted therapies for treating cancer rely on differential sensitivity of normal and
cancer tissue to the inhibition of cellular processes. Our group previously identified
COPZ1 as a potential therapeutic target because its inhibition selectively kills cancer
cells [35]. The COPZ1 gene and its paralogue COPZ2 encode the ζ1-COP and ζ2-
COP proteins respectively. The incorporation of one of the ζ-COP proteins is essential
for the formation of functional coatomer protein complex I (COPI) [38]. While there
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is some evidence for distinct functions of ζ1-COP containing and ζ2-COP containing
COPI complexes [39], depletion of either ζ1-COP or ζ2-COP in normal cells does
not inhibit cell growth or survival. This is because both COPZ1 and COPZ2 are
expressed in normal cells and depletion of a single ζ-COP protein is compensated
for by incorporation of the paralogous gene product into the COPI complex [35].
Importantly, many different cancers have silenced the COPZ2 gene resulting in their
dependence on COPZ1 ζ-COP production and proper COPI function [35]. Because
COPI is essential for retrograde transport (Golgi to ER) and Golgi stack maintenance
[37] as well as other cellular processes [188], cells with impaired COPI suffer from
Golgi collapse, ER stress [189], and ultimately die if COPI function is not restored.
ER stress occurs when the protein load in the ER surpasses its capacity to properly
fold and distribute proteins [190]. When the ER encounters such stress it activates
the unfolded protein response (UPR). The UPR is a multi-arm signaling pathway
with three ER membrane-resident sensors - endoplasmic reticulum to nucleus sig-
naling 1 (IRE1α), eukaryotic translation initiation factor 2 alpha kinase 3 (PERK),
and activating transcription factor 6 (ATF6α) [191]. These sensors are maintained
in an inactive state through interaction with the ER chaperone BIP (also called
HSP5/GRP78). When unfolded proteins accumulate in the ER, BIP dissociates from
IRE1α, PERK, and ATF6α allowing them to begin signaling [192]. UPR induction
results in (i) a global reduction in protein synthesis mediated by eIF2α phosphory-
lation, (ii) an upregulation of genes important for ER homeostasis (protein folding,
lipid synthesis, and protein degradation), (iii) and apoptosis, mediated by CHOP and
ASK1, if ER stress cannot be resolved [191, 193]. Whether UPR signaling results in
survival or death depends on the strength and duration of the ER stress [194].
The ability of cells to undergo tightly controlled cell death is an essential function
for normal physiology. In cancer cells, apoptotic pathways are often altered or dis-
mantled through silencing of key genes [10, 11]. It is therefore important to discern
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the specific signaling pathways involved in apoptotic signaling which are activated by
therapeutic intervention. This information can be used to predict the development
of therapeutic resistance as well as synergistic therapeutic approaches.
To understand the mechanism of cell death and the role of ER stress and the
UPR in cancer cells with inhibited COPZ1 function, we studied the effects of COPZ1
depletion in a panel of cancer cell lines. We found that disruption of COPI function
by depletion of COPZ1 disrupted Golgi structure and subsequently induced apoptotic
cell death. We show that COPZ1 depletion and Golgi disruption produce ER stress
and activation of the UPR. We extended these results by testing whether inhibition of
apoptotic signaling from the UPR could rescue cells from COPZ1-depletion induced
cell death and show that the UPR is not the primary mechanism of apoptotic cell
death and points to possible alternative mechanisms.
3.3 Materials and Methods
Cell lines
MDA-MB-231, HeLa, U2OS, DU145, and PC3 cell lines were obtained from Ameri-
can Type Culture Collection. BJ normal foreskin fibroblasts, immortalized with hu-
man telomerase reverse transcriptase (line BJ1-hTERT) were obtained from Clontech
Laboratories. HeLa, U2OS, DU145, MDA-MB-231, and PC3 cell lines were grown
in DMEM with 10% FC2. BJ-hTERT fibroblasts were maintained in BJ-hTERT
medium (4:1 DMEM/M199) supplemented with 1 mM of sodium pyruvate and 10%
FBS.
siRNA transfection
siRNA transfections in 96-well plates were performed using a reverse transfection
method. Briefly, siLentFect (Bio-Rad, Hercules, CA) was premixed with Opti-MEM
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medium (ThermoFisher Scientific, Waltham, MA) in the culture plate at 0.075 ul
siLentFect per 20 ul of Opti-MEM per well according to manufacturer’s protocol. 2.5
ul of 1 uM siRNA solution was added to the premixed siLentFect/Opti-MEM and
the siLentFect/Opti-MEM/siRNA mixture was incubated at room temperature for
20-30 min. 230 ul of cells were added to premixed siRNA/siLentFect complexes at
a seeding density of 5,000 cells per well in 96-well plate. siRNA treated cells were
grown for up to 5 days at 37oC in 5% CO2.
siRNA transfections in 6-well plates were performed using fast-forward trans-
fection method. Briefly, siLentFect was premixed with Opti-MEM media at 2.5 ul
siLentFect per 250 ul of Opti-MEM per well according to manufacturer’s protocol. 2.5
ul of 10 uM siRNA solution was added to the premixed siLentFect/Opti-MEM and
the siLentFect/Opti-MEM/siRNA mixture was incubated at room temperature for
20-30 min. 2.3 ml of cells were plated at 2.5 x 105 cells per well followed by addition
of siRNA complexes. siRNA treated cells were grown for 4 days at 37oC in 5% CO2.
siRNAs targeting COPZ1, CHOP, IRE1α, ATF6α, and PERK were ON-TARGET
plus SMARTpools (GE Healthcare, UK).
MTT assay
5 x 103 cells were plated in each well of 96-well plates. After treatment (see siRNA
transfection above), MTT reagent (Sigma, MO) was added to each well at a concen-
tration of 250 ug/ml and incubated at 37oC for 2 hrs. Media was removed and MTT
precipitate was dissolved with 100 ul per well of DMSO and mixed well. Absorbance
was read at 570 nm.
RNA extraction and qRT-PCR
Cells were washed with PBS and RNA was extracted with RNeasy kit according to
the manufacturer’s protocol (Qiagen, Hilden, Germany). 1 ug of RNA was used to
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generate cDNA according to the manufacturer’s protocol using iScript cDNA synthe-
sis kit (Bio-Rad, CA). RNA was amplified and gene expression was measured using
SYBR green super mix on a CFX384 Real time PCR (BioRad) according to the
manufacturer’s protocol. qRT-PCR results were obtained from 4 independent exper-
iments. The following primers were used for quantitative analysis (Integrated DNA
Technologies, IA):
CHOP forward - GTCTAAGGCACTGAGCGTAT
CHOP reverse - CTTTCAGGTGTGGTGATGT
XBP1(s) forward - TGCCCTGGTTGCTGAAGAGGAGG
XBP1(s) reverse - GCCTGCACCTGCTGCGGACTC
BIP forward - TGCAGCAGGACATCAAGTTCTTGCC
BIP reverse - GCTGGTACAGTAACAACTGCATGGG
IRE1α forward - CATGCCGAAGTTCAGATGGAATC
IRE1α reverse - CATTGGACACAAAGTGGGACATC
PERK forward - GCCAATGGGATAGTGACGAAATG
PERK reverse - CAATAAATCCGGCTCTCGTTTCC
ATF6α forward - TATTCTTCAGGGTGCTCTGGAAC
ATF6α reverse - TGTGGTCTTGTTATGGGTGGTAG
GAPDH forward - CCATCACCATCTTCCAGGAGCG
GAPDH reverse - AGAGATGATGACCCTTTTGGC
RPL13A forward - AGATGGCGGAGGTGCAG
RPL13A reverse - GGCCCAGCAGTACCTGTTTA
TBP forward - GCCATAAGGCATCATTGGAC
TBP reverse - AACAACAGCCTGCCACCTTA
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TUNEL assay
Cells were trypsinized and collected by centrifugation at 300 x g for 5 min and re-
suspended in 0.5 ml of 1% BSA in PBS. Resuspended cells were fixed by drop-wise
addition of 0.5 ml of freshly prepared 1% paraformaldehyde (PFA) in PBS (pH 7.4,
pre-warmed to 37oC) for 15 min. PFA was removed and cells were washed with 1%
BSA in PBS before addition of 100% ethanol (2 ml drop-wise). Fixed cells were stored
at -20oC. Following fixation, cells were permeabilized and labeled using Cell Death
Detection Kit (Roche, Basel, Switzerland). The number of TUNEL positive cells was
determined by flow cytometry using BD LSR II Flow Cytometer (BD Biosciences,
NJ).
Fluorescent microscopy
Cells cultured on glass coverslips (Bellco Glass) were fixed with 3.7% paraformalde-
hyde for 15 min and permeabilized with 0.5% Triton X-100 for 5 min. The coverslips
were incubated in 3% BSA for 1 hr at room temperature. Blocked coverslips were
incubated with mouse GM130 primary antibody (BD Biosciences, CA) and DAPI
(Invitrogen, CA). The secondary antibody was Cy3-conjugated goat anti-mouse IgG
(Jackson Laboratory, ME). Images were acquired with a PlanApo/N 60/1.42 NA
objective on an Olympus IX81 microscope. Hamamatsu C10600 camera gain and
exposure time settings were controlled with Metamorph Basic. Processing of images
(merging and brightness adjustment) was performed evenly across all images using
Fiji software [155, 154].
Small molecule inhibitor
NQDI-1 inhibitor of ASK1 (Tocris, Bristol, UK) was used at 10 uM. Cells were plated
in 6-well plates and transfected as described above with control or COPZ1 siRNAs.
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Inhibitors were added for 48 hrs 2 days after transfection.
Western blot
3 x 105 - 3 x 106 cells per sample were lysed with TNT lysis buffer (20 mM Tris HCl,
pH 7.5, 200 mM NaCl, 5 mM EDTA, 1% Triton X-100) supplemented with 1mM
DTT and Pierce Protease Inhibitor cocktail (Thermo Fisher Scientific, MA). Pro-
tein concentration was measured using Pierce BCA protein assay kit (Thermo Fisher
Scientific, MA) according to the manufacturer’s protocol. Lysates were subjected
to Western Blot analysis with primary antibodies: PARP (Cell Signaling Technol-
ogy, Cat. No. 9542P), CHOP (ThermoFisher, Cat. No. MA1-250), COPZ1 (Santa
Cruz Biotechnology, Cat. No. sc-13349), β-Actin (Thermo Scientific, Cat. No.
MA5-15739), and corresponding (HRP)-conjugated secondary antibodies (Thermo
Scientific, Cat. Nos. 31460, 31430). Images were obtained using ChemiDoc Touch
Imaging System (Bio-Rad, CA). Western blot data represent at least three indepen-
dent experiments.
Statistical analysis
Significance was determined by two sided Welch’s t-tests. Holm-Sidak correction for
multiple testing was used when necessary. T-tests and multiple testing corrections
were performed with GraphPad Prism (GraphPad Software, CA).
3.4 Results
COPZ1 depletion induces apoptosis in multiple cancer cell lines
Previously, we showed that depletion of COPZ1 selectively kills cancer cells through
loss of COPI function while normal cells were not affected. Normal cells are not
sensitive to COPZ1 depletion because they are able to compensate for the loss of
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COPZ1 through expression of its paralogue COPZ2 [35]. To study the effects of
COPZ1 depletion on cancer cells from various backgrounds, COPZ1 was depleted
by siRNAs in DU145 (prostate), U2OS (osteosarcoma), PC3 (prostate), and HeLa
(cervical) cell lines. At 2, 4, and 6, days after COPZ1 depletion apoptosis was moni-
tored by TUNEL assay (Figure 3.1). The TUNEL assay results showed that all cell
lines tested were sensitive to COPZ1 depletion and that the type of cell death was
specifically apoptosis.
COPZ1 depletion causes Golgi collapse in cancer cells
To better understand the physiological consequences of COPZ1 depletion, the Golgi
structure was monitored in these cell lines as well as BJ-hTERT normal fibroblast
cells. Imaging at 72 hours after transfection with siRNAs against COPZ1 showed
that Golgi disruption occurs in all tested cancer cell lines but not in the normal cell
line (Figure 3.2). This result suggested to us that the mechanism by which apoptosis
is signaled could originate as a consequence of improper protein trafficking caused by
Golgi collapse.
COPZ1 depletion activates the Unfolded Protein Response
Disruption of the Golgi has been shown to result in redistribution of Golgi proteins
to the ER [189], disruption of autophagy [188], and activation of the UPR [195]. We
tested whether COPZ1 depletion and subsequent Golgi collapse resulted in activation
of UPR signaling. To measure UPR activation, we monitored the expression of heat
shock protein family A (Hsp70) member 5 (HSPA5, also called BIP) and DNA damage
inducible transcript 3 (DDIT3, also called CHOP), as well as the splicing of XBP1
by IRE1α. COPZ1 depletion enhanced the expression of BIP and CHOP as much
as 4.5 fold 4 days after transfection. Additionally, XBP1 splicing was significantly
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enhanced (Figure 3.3). Together, these results show that COPZ1 depletion leads to
collapse of the Golgi apparatus and activation of the UPR signaling cascade.
CHOP knockdown provides mild protection from COPZ1 depletion-
induced cell death
The UPR signaling cascade is responsible for both protection from cell death as well as
promotion of cell death during ER stress. The ultimate result of ER stress depends on
the intensity and duration of the stress. Prolonged ER stress tips the balance of UPR
signaling toward cell death [191]. The primary mechanism of cell death signaling from
the UPR is through PERK/CHOP [196]. To test whether UPR signaling is directly
responsible for apoptotic cell death caused by COPZ1 depletion, we inhibited the
PERK/CHOP arm of the UPR by siRNA depletion of CHOP in conjunction with
COPZ1 depletion. Depletion of CHOP alone in multiple cancer cell lines did not cause
cell death, as measured by increased PARP cleavage (Figure 3.4a). COPZ1 depletion
caused a large increase in PARP cleavage and apoptosis in the absence of CHOP
siRNA and caused the activation of CHOP expression. Interestingly, the depletion
of both CHOP and COPZ1 with siRNAs partially decreased PARP cleavage relative
to COPZ1 alone. This result was observed in DU145, U2OS, and PC3 cells but not
in MDA-MB-231 (Figure 3.4a). These data suggest that the UPR may play a role in
apoptotic signaling caused by COPZ1 depletion but that CHOP inhibition alone is
not sufficient to rescue cells from their apoptotic fate.
Inhibition of IRE1α/ASK1 signaling provides mild protection from
COPZ1 depletion-induced cell death
IRE1α can also activate CHOP signaling through p38 MAPK [197] (also known as
ERK/MAPK1); however, IRE1α can also signal cell death through ASK1 mediated
activation of JNK [198, 199]. To test whether IRE1α/ASK1 was primarily responsible
55
for cell death signaling when COPZ1 was depleted, ASK1 was inhibited with the small
molecule inhibitor NQDI-1. NQDI-1 did not cause cell death alone and provided
similar protection to cell death as that observed with the depletion of CHOP in
conjunction with COPZ1 depletion (Figure 3.4b). Similar to CHOP depletion, NQDI-
1 produced mild protection from cell death, as measured by PARP cleavage, in DU145,
U2OS, and PC3 cells but not in MDA-MB-231 cells. This experiment also pointed
to a potential role of the UPR in cell death signaling after COPZ1 depletion but did
not produce the strong effect expected from the primary signaling pathway.
Blockade of UPR signaling does not promote survival after COPZ1
depletion
Because the UPR has multiple signaling arms which have overlapping functionality we
hypothesized that if inhibition of PERK or IRE1α cell death signaling could alleviate
apoptosis after COPZ1 depletion then inhibition of only one of these mechanisms
at a time may leave the other free to signal cell death and thus explain the mild
effect observed in Figure 3.4a and 3.4b. To test whether this was the case, we used
siRNAs to deplete all 3 of the primary UPR sensors - IRE1α, PERK, and ATF6α
- (Figure 3.4c) to prevent any UPR cell death signaling during COPZ1 depletion.
Interestingly, depletion of all 3 arms of the UPR signaling cascade in combination with
COPZ1 depletion produced almost identical results as those observed with inhibition
of IRE1α/ASK1 and PERK/CHOP with COPZ1 depletion (Figure 3.4d). Together,
these results provide strong evidence that while the UPR signaling cascade is activated
upon COPZ1 depletion, it is not the primary means by which COPZ1 depletion
activates apoptotic cell death.
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3.5 Discussion
The signaling pathways by which a cell balances the decision between cell death and
survival are complex and not completely understood [200, 201, 202, 203]. Complicat-
ing this is the fact that many of these pathways have a significant amount of cross-talk
[204, 205]. Furthermore, the ability of cancer cells to evade apoptosis has been estab-
lished as one of the hallmarks of cancer (for review see [10] and [11]). Together these
facts show that deciphering which signaling pathways are involved in the cellular de-
cision to undergo apoptosis can be exceedingly difficult. Our group [35] and others
[188, 195, 206] have shown that inhibition of the COPI complex, through depletion of
critical components of the complex, results in apoptotic cell death. We extended our
original study beyond PC3 cells to include cancer cell lines of different origin including
cancer cell lines of different origins DU145 (prostate), U2OS (osteosarcoma), HeLa
(cervical), and MDA-MB-231 (breast). Our results show that they are all sensitive
to COPZ1 depletion and undergo apoptotic cell death.
The COPI complex is required for Golgi function and proper protein trafficking
and disruption of the Golgi has been shown to cause ER-stress [189]. Because of
this, we looked at cell death signaling originating from the ER. We show for the
first time that the UPR, a known apoptotic signaling cascade originating in the ER,
is activated by COPZ1 depletion in cancer cells. This result for COPZ1 depletion
agreed with the results obtained by Claerhout et al. who tested the effects of multiple
other components of the COPI complex and further establishes the role of ER stress
and the UPR in COPI depletion [195].
Our study extends beyond that of other studies looking at the effects of COPI
inhibition by attempting to identify a causal link between a known cell death signaling
cascade and the depletion of COPZ1. We showed that inhibition of COPI function
by depletion of COPZ1 in cancer cells activates apoptotic cell death even when the
apoptotic arms of the UPR signaling pathway are inhibited. Furthermore, complete
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inhibition of UPR signaling by coordinated depletion of IRE1α, PERK, and ATF6α
was not able to significantly increase survival of cells with inhibited COPI function.
Our results suggest that activation of the UPR does not play a primary role in the
activation of apoptotic cell death during COPI inhibition (Figure 3.5).
While this study has not yet identified the primary mechanism by which apoptotic
cell death is signaled after loss of COPI function, it does show that UPR activation
and subsequent apoptosis are not always causally linked. This is an important con-
clusion as the UPR has been shown numerous times to play both pro-survival and
pro-death roles during ER-stress [191].
Preliminary results (data not shown) suggest that COPZ1 depletion and subse-
quent loss COPI function in cancer cells alters mitochondrial function directly and
specifically point toward the production of ROS in the mitochondria as mechanism































































































Figure 3.1: COPZ1 depletion activates apoptosis in multiple cancer cell lines. DU145, U2OS, PC3,
and HeLa cells were transfected with control or COPZ1 siRNA (5 nM). Apoptosis was monitored by
TUNEL assay at 48, 96, and 144 hrs after transfection. Values are percentage of TUNEL positive
cells for 3 independent experiments at each time point with error bars +/- 1 SD. Significance
determined by two-tailed t-test (P-values are U2OS: 7.5 x 10−5; HeLa: 2.0 x 10−4, 1.1 x 10−3;
















Figure 3.2: Collapse of the Golgi apparatus after COPZ1 depletion in cancer cells. Normal BJ-
hTERT cells and DU145, U2OS, PC3, and MDA-MB-231 cancer cell lines were treated with control
or COPZ1 siRNA (5 nM) and stained with DAPI (Nuclei, Blue) and Cy5-linked anti-GM130 anti-
body (Golgi, Red). Loss of tubular structure and close nuclear localization of GM-130 are indicative
of Golgi collapse.















































Figure 3.3: COPZ1 depletion activates the unfolded protein response. PC3 cells treated with control
or COPZ1 siRNAs (5 nM) show that COPZ1 depletion upregulates the expression of UPR induced
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Figure 3.4: Inhibition of UPR signaling does not significantly improve survival of cancer
cell lines after COPZ1 depletion. (a) Treatment of DU145, U2OS, PC3, and MDA-MB-231
cells with control, CHOP or COPZ1 siRNA (10 nM) for 4 days. COPZ1 depletion strongly
induces PARP cleavage which showed mild attenuation by concomitant inhibition of the
PERK/CHOP arm of the UPR pathway through depletion of CHOP in DU145, U2OS, and
PC3 cell lines but not in MDA-MB-231. COPZ1 depletion also induces CHOP expression
in all cell lines. (b) Inhibition of IRE1α/ASK1 with NQDI-1, a ASK1 inhibitor, mildly
attenuates COPZ1-depletion mediated PARP cleavage in DU145, U2OS, and PC3 cell lines
but not in MDA-MB-231. (c) qRT-PCR analysis of ATF6α, IRE1α, and PERK depletion in
PC3 cells treated with a 10 nM mixture of siRNAs against all 3 genes (UPR blockade). (d)
MTT analysis of cells treated with control or COPZ1 siRNAs in combination with control
or UPR blockade siRNAs (siUPR) for 4 days. siRNA mediated UPR blockade does not
significantly improve survival of PC3 cells after siRNA depletion of COPZ1. Bars indicate

























Figure 3.5: Mechanism of cancer specific cell death induced by COPZ1 depletion. (a) Proposed
mechanism of cell death caused by COPZ1 depletion and subsequent COPI inhibition. (b) Results
from this study show that the UPR is not the primary mechanism of signaling apoptosis although
it does contribute to cell death signaling.
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Chapter 4
CLASH reveals new targets of
microRNA-148/152 family1
1David Oliver, Hao Ji, Samuel Lee, and Michael Shtutman. To be submitted to Genome Biology
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4.1 Abstract
MicroRNAs (miRNAs) play an important part in cancer development and progres-
sion. Their regulation of multiple targets makes them important post-transcriptional
regulators. Because of this, miRNAs have been extensively studied but the rules
which govern their targeting have not yet been fully elucidated. In addition, the
role of miRNA families has not been thoroughly studied and their biological impor-
tance remains enigmatic. The microRNA-148/152 family consists of three miRNAs
– miR-148a, miR-148b, miR-152 – which are often dysregulated in various cancers.
MiR-148a is transcribed as an independent transcript while miR-148b and miR-152
are intronically encoded within the COPZ1 and COPZ2 genes respectively.
We previously found COPZ1 to be a valid target for cancer therapy. The sensitiv-
ity of cancer cells to COPZ1 inhibition is dependent on the silencing of the paralogous
COPZ2 gene. The COPZ2 gene is silenced in many different cancer types and is hy-
pothesized to be driven by the necessity to silence the encoded miR-152. Interestingly,
all members of the microRNA-148/152 family share a common seed sequence which
is considered the main determinant for what mRNAs will be the target of an miRNA.
This fact makes it difficult to isolate specific targets of miR-152 which would drive
COPZ2 silencing over that of COPZ1/miR-148b. To begin to understand the role of
the microRNA-148/152 family in cancer and the reason for the specific silencing of
COPZ2/miR-152 during cancer progression, we use a new approach for identifying
miRNA targets called Cross-linking, Ligation, And Sequencing of Hybrids (CLASH).
This technique provides a global snapshot of miRNA/mRNA interactions within the
cell. We use this approach to show that microRNA-148/152 family work both co-
ordinately and as individuals to regulate signaling pathways important for growth,
adhesion, and endothelial-to-mesenchymal transition.
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4.2 Introduction
MiRNAs are small (18-22nt long), non-coding RNAs [40] which can be transcribed
as independent transcripts or as a portion of a host gene [41, 42]. The primary
miRNA (pri-miRNA) is processed by multiple processing complexes to generate the
mature miRNA [49]. The guide strand of the mature miRNA duplex is then as-
sembled into the RNA-Induced Silencing Complex (RISC) through association with
the argonaute protein (In mammalian cells AGO2 is the primary argonaute protein)
[50]. The miRNA then guides the RISC complex to target mRNAs to prevent their
translation through incompletely understood mechanisms. The primary mechanisms
by which RISC suppresses target mRNA translation are mRNA destabilization (5’
de-capping or 3’ de-adenylation) and translational repression (through disruption of
the translational machinery) [60, 61].
The rules which govern miRNA/mRNA interactions are not completely under-
stood. Target prediction algorithms have made use of an established set of rules to
attempt to help guide research efforts; however, these methods do not identify all
targets and lack the sensitivity to distinguish targets between highly similar miRNAs
[73]. This is because most algorithms depend on the “seed” sequence of the target-
ing miRNA, the evolutionary conservation of mRNA target sites, and mRNA target
sites within the 3’-untranslated region (3’UTR) of genes [64]. The lack of sensitivity
and the inability to explain all miRNA/mRNA interactions has driven researchers
to develop better methods for the cell-wide identification of miRNA/mRNA interac-
tions. These approaches use UV-cross linking of the AGO/miRNA/mRNA complex
followed by immunoprecipitation of the AGO2 protein to capture miRNA targets
in-vivo [74, 75]. While the initial variations of these approaches were dependent
on bioinformatic imputation (prediction) of miRNA/mRNA targets, the most recent
protocols no longer require this step. Cross-linking, ligation, and sequencing of hy-
brids (CLASH) [78, 79] adds a miRNA-to-mRNA ligation step which results in the
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generation of chimeric sequences of targeting miRNA and target mRNA. Through
analysis of these chimeric reads, miRNA targets can be established without the need
for statistical modeling or target prediction.
MicroRNAs have been shown to play key roles in controlling signaling pathways
important for disease. More specifically, their role in cancer has been extensively stud-
ied and many miRNAs have been shown to regulate key genes responsible for cancer
progression including oncogenes and tumor suppressors [207, 208]. Furthermore, their
expression levels are often indicative of disease status and have been heavily studied
for their potential as biomarkers [209]. Several groups have also shown their effi-
cacy as potential therapeutics which have many advantages over single target, small
molecule approaches [210]. These factors point to the importance of studying the role
of microRNAs in cancer.
We previously found that COPZ1 was a potential target for therapy [35]. The
cancer-specific sensitivity of cells to COPZ1 targeting is a consequence of the silencing
of its homologous gene COPZ2. These genes were found to encode the miR-148b and
miR-152 microRNAs within their first intron [88]. These two miRNAs are part of
the microRNA-148/152 family which also includes miR-148a. We also previously
showed that miR-152 was tumor-suppressive [35] and proposed that the reason for
COPZ2 silencing was the intronically encoded miR-152. However, since miR-148a,
miR-148b, and miR-152 share a common seed sequence we were unable to use target
prediction algorithms to identify targets which would be unique to miR-152 and
explain its specific downregulation. Furthermore, many studies had been performed
on individual members of this family without addressing whether other members of
the same family also targeted the gene of interest. To begin to understand how this
miRNA family functioned in cancer, and whether we could identify targets which
would explain the specific silencing of miR-152, we used a modified version of the
CLASH protocol to identify the full set of target genes of the microRNA-148/152
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family in prostate cancer cells.
4.3 Materials and Methods
Generation of miRNA expressing cell lines
The DU145 cell line was obtained from American Type Culture Collection (ATCC)
and grown in DMEM supplemented with 10% FC2 without antibiotics. Lentiviral
transduction of the miRNA expression vectors (System Biosciences, CA) containing
miRNAs and GFP reporter was carried out as described [148] using pCMV-∆8.9
and pVSV-G packaging constructs. The vector plasmid, pCMV-∆8.9, and pVSV-
G DNA were mixed at 5:4:1 ratio and co-transfected, using the polyethylenimine
protocol [149], into 293FT cells. Lentivirus-containing media was harvested at 48
and 72 hours and used to infect DU145 cells. DU145 cells expressing control, miR-
148a, miR-148b, or miR-152 were sorted 1 week after infection with BD LSR II Flow
Cytometer (BD Biosciences, NJ) selecting for cells highly expressing GFP. Expression
of miRNAs was confirmed by qRT-PCR (see Figure 4.1 for Schema).
RNA extraction and qRT-PCR
Cells were washed with PBS and RNA was extracted with RNeasy kit according to
the manufacturer’s protocol (Qiagen, Hilden, Germany). 1 ug of RNA was used to
generate cDNA according to the manufacturer’s protocol using iScript cDNA synthe-
sis kit (Bio-Rad, CA). RNA was amplified and gene expression was measured using
SYBR green super mix on a CFX384 Real time PCR (BioRad) according to the
manufacturer’s protocol. qRT-PCR results were obtained from 4 independent exper-
iments. The following primers were used for quantitative analysis (Integrated DNA
Technologies, IA):
IGFBP5 forward - CCCAATTGTGACCGCAAAGG
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IGFBP5 reverse - AGGTGTGGCACTGAAAGTCC
ERRFI1 forward - GCTCAGGAGCGCCTAATACC
ERRFI1 reverse - GTGGAAGAGGCCTAGAACCC
ITGA5 forward - CAGGGTTACTGCCAAGGAGG
ITGA5 reverse - TGCAATCTGCTCCTGAGTGG
GAPDH forward - CCATCACCATCTTCCAGGAGCG
GAPDH reverse - AGAGATGATGACCCTTTTGGC
RPL13A forward - AGATGGCGGAGGTGCAG
RPL13A reverse - GGCCCAGCAGTACCTGTTTA
TBP forward - GCCATAAGGCATCATTGGAC
TBP reverse - AACAACAGCCTGCCACCTTA
Total RNA for miRNA qRT-PCR was isolated using TRIzol reagent (Ther-
moFisher, MA) according to the manufacturer’s protocol. Preparation of miRNAs
for qRT-PCR was performed as previously described [211]. Briefly, 1 ug of total RNA
was used for poly-A tailing with E. coli Poly (A) Polymerase I (E-PAP) (NEB, MA)
followed by reverse transcription to generate first strand cDNA using a Poly(T) re-
verse transcription adapter (5’-GCGAGCACAGAATTAATACGACTCACTATAG-
G(T)12VN-3’). Expression of miRNAs was quantified as described above with
miRNA specific primers (miR-148a: TCAGTGCACTACAGAACTTTG; miR-148b:
TCAGTGCATCACAGAACTTTG; miR-152: TCAGTGCATGACAGAACTTG) in
combination with a universal PCR primer (5’-GCGAGCACAGAATTAATACGAC-
3’). All oligonucleotides were purchased from Integrated DNA Technologies.
RNA sequencing procedure and analysis
Poly(A) RNA from DU145 and PC3 cells overexpressing miRNA-148/152 family
members was prepared for sequencing with NEBNext Ultra RNA Library Prep Kit
for Illumina (New England BioLabs, MA). 75 bp, single end (SE) sequencing was
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performed at Cornell Epigenomics Core Facility using Illumina HiSeq2000. Resulting
reads were obtained in FASTQ format. FASTQ data were aligned to the reference
genome (hg38 downloaded from http://hgdownload.soe.ucsc.edu/goldenPath/) using
STAR aligner [212]. Aligned reads were filtered for low quality and duplicate align-
ments with samtools [213] and counted using featureCounts [214]. Count data were
processed for differential expression analysis in R [150] using edgeR [215, 216, 217].
Cross-linking ligation and sequencing of hybrids (CLASH)
For each of the 3 biological replicates, 15 150 mm plates of DU145 cells expressing
control, miR-148a, miR-148b, or miR-152 were cultured to 70 - 90% confluence and
cross-linked on ice with Stratalinker (company, state) at 365 nm for 4000 uJ/cm2
rotated and then irradiated again for 2000 uJ/cm2. Cells were scraped and centrifuged
at 300 x g for 4 min and cell pellets were flash frozen in liquid nitrogen.
Prior to immunoprecipitation, cell pellets were thawed on ice and resuspended on
ice with PXL buffer supplemented with protease inhibitor cocktail (Sigma-Aldrich,
MO). The cell suspension was treated with RQ1 DNase (Promega, WI) and 1:100,000
dilution of RNase A (Promega, WI) and incubated at 37oC for 10 min at 1000 rpm
(rotary shaker shaking). RNase was quenched with RNasin Plus (Promega, WI)
and samples were transferred to pre-chilled ultracentrifuge tubes. Samples were cen-
trifuged at 4oC for 30 min at 32,000 g (30,000 rpm - TLA-120.2 Rotor in Optima
Max-E).
Cross-linked AGO2/miRNA/mRNA complexes were immunoprecipitated from
cleared lysates with AGO2 specific antibody (Sigma-Aldrich, MO). Specifically, AGO-
2 antibodies were hybridized to protein G-conjugated Dynabeads (ThermoFisher,
MA) at room temperature for 40 min. Cleared samples were added to AGO2-
hybridized dynabeads and incubated at 4oC for 4 hrs. All remaining steps were
performed on bead.
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The 5’ end of RNase treated mRNAs (within the AGO2/miRNA/mRNA com-
plex) were repaired with Polynucleotide Kinase (PNK) treatment (NEB, MA). The
repaired 5’ mRNA was then ligated to the 3’ end of the targeting miRNA by T4 RNA
ligase 1 (NEB, MA) treatment. The 3’ end mRNAs was repaired by dephosphory-
lation with Alkaline Phosphatase (NEB, MA) treatment. Finally, miRNA/mRNA
ligated products (as well as non-ligated miRNAs and mRNAs) were were released
from AGO2 and the dynabeads by proteinase K treatment (Sigma-Aldrich, MO).
RNA species were isolated from the samples using RNA isolation kit according to the
manufacturer’s protocol (Zymo Research, CA). Final purified RNA was eluted from
the columns with water. RNA concentration was quantified by Quant-iT RiboGreen
RNA Assay Kit (ThermoFisher, MA) according to the manufacturer’s protocol. A
detailed protocol for the modified CLASH procedure is located in the Appendix.
RNAs were prepared for sequencing with NEBNext Multiplex Small RNA Library
Prep Set for Illumina according to the manufacturer’s protocol with the following
adjustments: RNA input was ≈ 5 ng and 3’ SR Adaptor for Illumina, SR RT Primer
for Illumina, and 5’ SR Adaptor for Illumina were diluted 1:8 in order to decrease
adapter dimer formation.
PCR product obtained from the NEBNext kit were purified using QIAquick PCR
purification kit (Qiagen, Germany) according to the manufacturer’s protocol. Sample
quality and quantity was analyzed prior to sequencing using 2100 Bioanalyzer (Agi-
lent, CA). Samples were sequenced on the NextSeq 500 with 75 bp paired end reads
(Illumina, CA).
CLASH sequencing procedure and analysis
75/75 bp, paired end (PE) sequencing was performed using Illumina NextSeq500.
Resulting reads were obtained in FASTQ format. Processing of reads to identify
and extract chimeric reads (miRNA/mRNA hybrids) was performed by first split-
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ting the FASTQ files (FASTX Barcode Splitter) by the high-confidence miRNA
(miRBase v21) at the beginning or end of the read. Each miRNA containing read
was assigned to a new FASTQ to keep miRNA associated reads distinct for later
bioinformatic analysis. All reads had any sequencing adapters trimmed from the 5’
and 3’ ends before being aligned back to the reference human genome (hg38 down-
loaded from http://hgdownload.soe.ucsc.edu/goldenPath/) with STAR aligner [212].
Aligned reads were filtered using samtools [213] to remove reads that failed to align
uniquely or had low alignment quality score. Reads were assigned to features (Exons
or UTRs) and counted using featureCounts [214]. Visualization of alignments was
done in IGV [218, 219] and UCSC Genome Browser [220].
Pathway analysis
Genes differentially expressed at least 1.2 log fold change by over-expression of the
miR-148/152 family members were imported into Cytoscape 3.4 [221] and genes in-
volved in signaling pathways were identified using the GeneMANIA plugin [222] as
well as STRING v10 [223]. Nodes were colored with the median log fold change for
all samples. Continuous networks were analyzed for gene ontology enrichment with
the the BiNGO plugin [224].
Statistical analysis
Significance was determined by two sided Welch’s t-tests with Holm-Sidak correction
for multiple testing when necessary. T-tests and multiple testing corrections were
performed with GraphPad Prism (GraphPad Software, La Jolla CA).
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4.4 Results
Development of modified CLASH protocol
In order to study the effects of the microRNA-148/152 family on cancer cells, we sta-
bly infected DU145 cells with miRNA expression vectors containing a GFP reporter
element for easily identifying vector expressing cells (Figure 4.1). After infection, we
sorted the cells for high GFP expression and validated the miRNA expression with
qPCR. qPCR revealed that miR-148a and miR-152 were very highly over expressed
(>100 fold change) while miR-148b was over-expressed to a lesser extent (≈ 10 fold
change) (Figure 4.1). The normalized counts per million observed in the CLASH
datset for each miRNA after over-expression were miR-148a – 1.17x106, miR-148b –
7.25x103, and miR-152 – 6.34x105.
In order to identify targets of the microRNA-148/152 family we modified the
CLASH protocol [78, 79] to eliminate the use of a PTH-tagged argonaute protein.
As an alternative to PTH-tagged AGO2 over-expression, we used a validated AGO2
antibody (Sigma-Aldrich, MO, [Clone 11A9]) to immunoprecipitate native AGO2.
In addition, steps involving radio-labeling which were part of the original protocol
were omitted as they were necessary only for proof of principle. The resulting pro-
cedure requires only 4 days from start to sequencing. Figure 4.2a shows the basic
schema for the biochemical portion of the CLASH protocol The full protocol for this
procedure can be found in the appendix to this chapter on page 126. Three differ-
ent RNA species are obtained from this procedure – RNAs (≈ 58%), miRNAs (≈
40%), and miRNA/mRNA chimers (≈ 2%). The different RNA species generated
in this experiment complicate the bioinformatic analysis significantly compared to
traditional RNA sequencing analysis. Figure 4.2b shows the pipeline for processing
the sequencing reads prior to analysis. The code for this analysis is located in the
appendix to this chapter on page 132 and can also be downloaded from github (
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https://github.com/doliv071/CLASH ). Briefly, the workflow begins with splitting
the raw sequencing (FastQ) files based on the unique miRNA at the 5’ end of the
read or the reverse complement of the miRNA sequence at the 3’ end of the read
(having to search for the reverse complement can be avoided if a stranded RNA-seq
library prep kit is used. Split files are trimmed and prepared for aligning using and
re-paired with their paired end read (if a paired end library is prepared). Finally
sequences are aligned to the genome and the reads assigned to genomic features. The
miRNA-specific mRNA counts can then be used to identify targets of the miRNA of
interest (Figure 4.2b). While this analysis focuses on the microRNA-148/152 family,
all miRNAs are actually captured during this procedure which makes it an extremely
powerful technique for the analysis of microRNA regulation.
miRNA incorporation data from CLASH reveals microRNA-148/152
family specific effect
Since CLASH produces 3 different RNA species, we first analyzed the miRNA reads.
These reads show the incorporation of miRNAs into the AGO2 protein and gives a
snapshot of the miRNA activity within the cell at the time of the CLASH procedure.
Using miRBase’s (v21) list of high confidence miRNAs which contains 1,996 unique
miRNAs, we identified an average of 248 unique miRNAs associated with the AGO2
protein in our samples (Figure 4.3a). These miRNA reads were used to determine if
the over-expression of the microRNA-148/152 family members translated to increased
incorporation into the AGO2 protein and RISC complex. This analysis showed that
miR-148a and miR-152 showed enhanced AGO2 association (6.415 and 9.391 log
fold change, respectively) while the effect with miR-148b was not as strong but still
significant (2.357 log fold change) (Figure 4.3b).
Interestingly, this analysis also revealed that miR-195-5p was also incorporated
into the AGO2 protein at a higher level in all samples over-expressing microRNA-
73
148/152 family members. While the increased incorporation of miR-195 in samples
over-expressing the microRNA-148/152 family is intriguing, and could point to an
interesting co-regulation network, the overall size of the effect is small and is overem-
phasized by the fact that miR-195 does not appear to be associated with AGO2 in
the control samples.
To get a global picture of the effect of strong over-expression of a single miRNA on
the incorporation of other miRNAs into the RISC complex, we plotted the normalized
read counts from control sample against the over-expressing samples (Figure 4.3c).
This analysis shows that the only strongly affected miRNA was miR-100-5p, how-
ever, this miRNA was also strongly affected by miR-148b overexpressing, which was
relatively low. In addition, it’s decreased incorporation into the RISC complex was
not statistically significant suggesting that its disregulation is an artifact (Figure 4.3b
shows all significantly altered miRNAs). This is an extremely important result as it
shows that overexpression of the microRNA-148/152 family members does not change
the global microRNA/AGO2 interaction and thus results obtained from our CLASH
and RNA-seq dataset are representative of changes affected by the over-expressed
miRNA only.
Chimeric reads reveal targets of the microRNA-148/152 family
We next analyzed the chimeric reads specific to each of the over-expressed miRNAs.
When just taking chimeric reads into account at least 5 chimers across all samples
were required for them to be considered in this stage of the analysis. Figure 4.4 shows
the genes which met this criteria. miR-148a had the most chimeric reads followed
by miR-152. MiR-148b had the least and given the total expression levels of each
of these miRNAs (Figure 4.3c) this result was expected. Figure 4.4 inset shows the
numeric summarization of chimeric reads. MiR-148a had 85 total chimers of which
39 were found only in the miR-148a sample. MiR-152 had 57 total chimers of which
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18 were found to be unique to only miR-152. MiR-148b had 16 total chimers and
none were found to be unique to that sample. Interestingly, only 9 genes had more
than 5 chimeric reads and were found in all samples. Whether the distribution of
chimers with at least 5 counts across all samples is indicative of the potency of the
miRNAs or simply a result of the expression levels for these miRNAs is difficult to
determine. However, the fact that there are unique chimeric reads between the miR-
152 and miR-148a samples indicates that not all targets of the miRNAs within the
microRNA-148/152 family are shared targets.
Distribution of chimeric reads correlates with non-chimeric read
enrichment in miR-148a over-expressing samples
Figure 4.5a-c shows the differential association of non-chimeric reads with the AGO2
protein in miRNA overexpressing samples relative to control samples. Non-chimeric
reads are associated with the AGO2 protein but are not ligated to an miRNA. If a
gene has more non-chimeric reads in the miRNA over-expressing sample relative to
the control sample then it is likely that the gene is associated with the AGO2 protein
more often because it is a target of the over-expressed miRNA. We considered non-
chimeric reads to be strong evidence for real targeting if they were enriched >5 log
fold or were enriched with an adjusted p-value <0.05. Since non-chimeric reads are
indirect evidence of miRNA/mRNA interactions we supplemented this data with
target prediction evidence (black X’s and top rug plot) and chimeric evidence (red
X’s and bottom rug plot). When adding these additional data points, we can see
that miR-148a and miR-148b overexpressing samples show a shift of chimeric and
predicted evidence toward the enriched (right) side of the plot. Interestingly this
effect was not observed with the miR-152 over-expressing sample. Figure 4.5d shows
that there are a large number of non-chimeric reads which are enriched in all three
samples but also many which are unique to individual samples. One of the most
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interesting results from this analysis was that the genes with the strongest evidence
from all 3 samples (MSMO1, YPEL2, CCNI, CYP4F11, GLMP, TFPI2, IGSF9B,
and CDHR2) were not predicted to be targets of the microRNA-148/152 family.
Integration of CLASH and RNA-seq datasets reveals extensive sig-
naling pathway regulation by the microRNA-148/152 family
To complete the analysis of this CLASH dataset, we merged it with RNA-seq data
using the same cell lines. Since one of the primary consequences of miRNA targeting
is the destabilization of their target mRNA, RNA-seq data can reveal miRNA targets
through decreased representation of target mRNAs between miRNA overexpressing
samples and controls. The addition of the RNA-seq dataset to the non-chimeric and
chimeric data provides 3 levels of evidence for the targeting of an mRNA by the
over-expressed miRNA. With the addition of decreased representation in the RNA-
seq dataset to the criteria for authentic targets, we relaxed the criteria for chimeric
reads (at least 1 chimeric read). We found a total of 182 chimers and 18 non-chimers
were supported by RNA-seq data in the miR-148a over-expressing samples and that
5 of these had all 3 levels of support (MSMO1, AHR, ZFP36, SIMC1, and TXNIP)
(Figure 4.6a left panel). The miR-148b over-expressing samples had 25 non-chimeric
reads with RNA-seq support and 11 chimeric reads with the same, but no genes had
support at all three levels (Figure 4.6a left panel). MiR-152 over-expressing samples
had 38 non-chimeric reads with RNA-seq support and 90 chimeric reads with the
same. A single gene had support at all three levels in this sample (ZNF204P)(Figure
4.6a left panel).
Next we asked if genes with added RNA-seq evidence were part of signaling path-
ways. Using GeneMANIA and STRING to identify signaling pathway in which the
list of RNA-seq supported genes were involved. We found that EGFR signaling was
the most strongly regulated signaling pathway in miR-152 over-expressing samples
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(Figure 4.6b). MiR-148a also regulated EGFR signaling as well as TGF/SMAD sig-
naling and integrin laminin signaling (Figure 4.7). These result suggest that the
microRNA-148/152 family are important regulators of growth, adhesion, and EMT.
4.5 Discussion
The identification of targets of miRNAs that play a causal role in cancer development
and progression is crucial to understanding when and why cancer cells alter the
microRNA-148/152 family expression levels. Target identification also gives insight
into whether or not a cell may be able to re-adjust the expression of a microRNA at a
later point without suffering deleterious consequences. Furthermore, there are many
open questions about what rules govern miRNA targeting. Studying the microRNA-
148/152 family provides us with an excellent model for answering these questions.
First, the microRNA-148/152 family members are dysregulated in multiple different
cancer types and a consensus has not been established about whether these miRNAs
work together or separately to regulate their targets. Second, miR-148b and miR-152
are encoded within the COPZ1 and COPZ2 genes, respectively. COPZ1 has been
shown to be a target for cancer therapy because of the silencing of the paralogous
COPZ2 gene. It was also shown that the encoded miR-152 was coordinately silenced
with the host gene [35]. It is therefore possible that, given the selection pressure of
therapeutic treatment targeting COPZ1, cancer cells may be able to re-express the
COPZ2 gene and its encoded miR-152 if the re-expression is not too deleterious to
the cells. This re-expression would then provide the cancer cells with a mechanism
of resistance. Identifying the targets of the microRNA-148/152 family are therefore
important for the development of COPZ1 as a therapeutic target for cancer treatment.
Finally, the conserved seed region across all three members of the microRNA-148/152
family provides an interesting model system for discovering the relative importance
of seed and non-seed regions of the miRNAs for targeting.
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Using a modified version of the CLASH protocol, we show that over-expression
of a single miRNA does not alter the global incorporation of miRNAs into the RISC
complex. Furthermore, we show that many targets of the microRNA-148/152 family
are shared but also that each member of the family seems to have it’s own set of
targets. Unfortunately we were not able to make a quantitative statement about
the efficiency of individual miRNAs due to the large variation in expression levels
of the miRNAs. However, we were able to identify a network of genes regulated by
the microRNA-148/152 family. Specifically, we found that miR-148a and miR-152
regulated EGFR signaling at multiple points (EGFR, ERBB3, NCKIPSD, PTEN,
ERRFI1, IRS1, and DUSP1) to control both growth and adhesion. Furthermore,
miR-148b showed extensive regulation of TGF (TGFBR2, SMAD3, and TGFA) and
integrin signaling (PXN, ITGA3, ITGA5, LAMA3, LAMA4, and PLEC). Interest-
ingly, many of the identified targets were not predicted by any of the target prediction
algorithms we searched (TargetScan, miRANDA, and DIANA-microT). This result
further emphasizes the importance of these types of studies to further advance the
field of microRNA research.
The use of several datasets to reveal pathways regulated by the microRNA-
148/152 family in cancer development and progression is a major step toward under-
standing this microRNA family. Further work on identification of consensus binding
motifs for each of the miRNAs in this family will also advance the ability of target



































































































































































































































Figure 4.1: Cellular system for studying the miRNA-148/152 family. To
generate DU145 cells stably expressing each of the three miRNA-148/152
family members or vector control, lentiviral miRNA expression constructs
were transfected into 293FT cells and lentiviral particles containing the
vectors were collected at 72 hrs and 96 hrs. Lentiviral particles were then
infected into DU145 cells. Cells were sorted for high GFP expression and






































































Figure 4.2: Schematic for a modified version of the CLASH procedure. (a) DU145 cells overex-
pressing a member of the miRNA-148a/152 family or control were treated with UV to cross-link
miRNA/mRNA/AGO2 complexes for immunoprecipitation. Mild RNase treatment is performed
to trim the associated mRNAs followed by PNK treatment to repair the 5’ end of the mRNA.
The 5’ end of the mRNA is then ligated to the 3’ end of the targeting miRNA. Finally, the 3’
end of the mRNA is repaired and the miRNA/mRNA hybrid is released by proteinase K digestion.
miRNA/mRNA hybrids (Chimers) are then purified for sequencing. (b) Bioinformatic analysis
of CLASH sequencing results begins by isolating all reads with a unique miRNA (no mismatches
allowed) from those without an associated miRNA. All reads then undergo adapter trimming to re-
move Illumina sequencing adapters. Because reads that are adapters or miRNAs only are removed
from the reads to be aligned, the remaining reads must be re-paired with their correct paired end
read. Finally, reads are aligned to the genome and reads falling within genes are counted. The
resulting dataset contains counts for all miRNAs including non-chimeric miRNA reads, chimeric
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Figure 4.3: Summary of cell-wide miRNA/RISC association profile. (a) Number of unique
miRNAs associated with the AGO2 protein within the RISC complex. Each bar represents a
biological replicate. Three biological replicates were performed for each miRNA overexpress-
ing DU145 cell line as well as the control cell line. (b) Heatmap of miRNAs with significant
differential incorporation into the RISC complex relative to control sample. Red is increased
association with the RISC complex, white is no-change, and blue is reduced association
relative to the control. (c) Scatter plots showing normalized counts for each miRNA in over-
expressing samples (y-axis) relative to control samples (x-axis). Counts were normalized
using the trimmed mean of m-values (TMM) and are represented as counts per million. The




































































































































Figure 4.4: CLASH identifies direct targets of the miRNA-148/152 family. Venn diagram of all
genes which had at least 5 chimeric reads across all miR-148/152 family members (103 chimers
of 1,125 total chimers). miR-148a had 85 total chimers, miR-152 had 57 total chimers and miR-
148b had 16 total chimers. miR-148a had 39 chimers in common with miR-152 and 16 chimers in
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Overlap of High Confidence
Non-Chimeric Reads
(d)
Figure 4.5: CLASH identifies mRNAs enriched in the RISC complex of miRNA-148/152 overex-
pressing samples. Sequencing reads which were not directly ligated to a targeting miRNA were
analyzed for differential enrichment in miRNA over-expressing samples relative to controls. (a)
Non-chimeric reads from miR-148a over-expressing DU145 cells were counted and their enrichment
calculated relative to control samples (gray points). Non-chimeric reads with strong evidence are
highlighted (blue circles). Genes with some chimeric evidence are marked with red X’s and genes
that were predicted as targets by DIANA, TargetScan, or miRANDA are indicated with black X’s.
(b) Non-chimeric reads from miR-148b over-expressing DU145 cells. (c) Non-chimeric reads from
miR-152 over-expressing DU145 cells. (d) Venn diagram displaying the number of genes with high
confidence non-chimeric reads identified in each sample and their relative overlap. Non-chimeric
reads were considered high confidence if they were significantly enriched (p < 0.05) or were enriched
at least 5 log fold change. In addition, non-chimeric reads with enrichment and additional target
prediction data or at least 3 chimeric reads were also considered high confidence.
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Figure 4.6: Integration of RNA-seq and CLASH datasets reveals miR-152 regulated signaling path-
ways. (a) Venn diagrams showing the distribution of CLASH reads which also had RNA-seq data
which supported their legitimacy as targets of the miRNA-148/152 family. Few genes had both
chimeric and non-chimeric reads which agreed with RNA-seq evidence (left 3 venn diagrams). While
non-chimeric reads dominated the large majority of the CLASH sequencing dataset, relatively few
were supported by RNA-seq data (right top and right bottom). (b) Network of signaling pathways
altered by overexpression of miR-152 in DU145 cells. All genes within the network were downreg-
ulated in the RNA-seq dataset (node color) and also had chimeric or non-chimeric (node outline)





















































































































































































































































































































































































































































































































Figure 4.7: Integration of RNA-seq and CLASH datasets reveals
miR-152 regulated signaling pathways. Network of signaling path-
ways altered by overexpression of miR-148a in DU145 cells. net-





Sequencing technology has pushed the boundaries of what was thought possible for
biological studies. With the application of sequencing to whole genome scale screens,
the major limitation becomes successful interpretation of large datasets and the iden-
tification of causal target genes. To improve the outcome of these types of large scale
screens, we developed a focused and pooled shRNA library screen combined with
sequencing and statistical analysis to identify genes with the potential to be targets
for the development of cancer therapeutics. Our approach reduces large sets of genes
obtained from a whole genome scale loss-of-function screen to a manageable sized
set of potential therapeutic targets which can be studied at meaningful depth by re-
searchers. We applied this approach to the results of a whole genome GSE screen with
>200 potential hits and reduced the list to <40 followup genes. Of these genes we
found that ribosomal protein L35a (RPL35A), archain 1 (ARCN1), and DEAD-box
helicase 24 (DDX24) showed strong potential for effective therapeutic intervention.
DDX24 was the most promising target with efficacy in cancer cell lines from multiple
different origins and independent of p53 status. Furthermore, DDX24 is a member
of a large family of RNA-helicases with a catalytic site which makes it an attractive
target for small molecule inhibitors, indeed, a selective small molecule inhibitor for
DDX3 has already been developed.
In our original whole genome GSE screen, the COPZ1 gene was identified as a
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potential target for cancer therapy. To better understand its potential as a therapeutic
target we studied multiple cancer cell lines from different origins to determine the
mechanism by which the depletion of COPZ1 kills these cells. We found that COPZ1
depletion causes apoptotic cell death in all cancer cell lines tested without significantly
harming normal cells. In addition, we found that COPZ1 depletion activated the
unfolded protein response (UPR) but that the UPR was not the primary cause of
apoptotic cell death.
In addition to exploring the mechanism by which COPZ1 depletion kills cancer
cells, we explored the functional importance of the microRNA-148/152 family of
microRNAs, two members of which are encoded within the COPZ1 and COPZ2
genes. We hypothesized that the selective silencing of COPZ2 was a consequence
of the encoded miR-152. We used CLASH to identify direct targets of each of the
miRNAs and found that the microRNA-148/152 family targets multiple pathways
important for growth and adhesion. In addition, the family seems to have a common
set of targets that a shared and also distinct targets that are unique to each miRNA
suggesting that miRNA families may provide more robust regulation than previously
expected.
Future directions
In Chapter 2 we developed an experimental and statistical approach for identifying
potential therapeutic targets. We used this approach to discover that knockdown of
DDX24 causes cancer-specific cell death. We extended these results to show that the
efficacy of DDX24 knockdown mediated cell death is not dependent on p53 status
and that multiple different types of cancer cell lines are sensitive to DDX24 targeting.
However, the identification of a potential therapeutic target is only the first step in
the drug discovery pipeline. Translating a potential therapeutic target into patient
treatment is a long and costly processes. The fact that DDX24 has a catalytic site and
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that other members of the DDX family have had small molecule inhibitors developed
for them is promising in this regard. The immediate future goal for this project is the
elucidation of the mechanism by which cancer cells are selectively sensitive to DDX24
inhibition. Concurrent with mechanistic studies, collaborations with chemists to
design selective small molecule inhibitors will also be necessary. The identification and
validation of DDX24 is only the first step but is a promising and exciting discovery.
In Chapter 3 we began elucidating the mechanism by which cancer cells signal
apoptosis when COPZ1 is depleted. Depletion of COPZ1 causes cancer specific loss
of COPI function and subsequent collapse of the Golgi apparatus. We originally
hypothesized that this would inhibit the cells capacity for protein processing and
thus activate stress responses originating in the Golgi or Endoplasmic Reticulum
(ER). We found that COPZ1 depletion induced ER-stress and activated the UPR
signaling cascade. Many studies have showed that extended ER-stress and UPR
signaling result in cell death. Interestingly, we found that while ER-stress and the
UPR were active during COPZ1 depletion inhibition of the UPR did not rescue cells
from their apoptotic fate. This de-coupling of prolonged UPR signaling and cell
death opened up many other potential pathways by which the cell may be signaling
apoptosis. The future direction of this work is to identify the specific mechanism
involved. Preliminary results in this direction suggest a mechanism mediated by
mitochondrial ROS production. This brings up many additional interesting questions
about the role of COPI in mitochondrial function.
In Chapter 4 we used a cutting edge technique to identify targets of the microRNA-
148/152 family. This work represents a significant advancement in the study of this
microRNA family. Many studies have shown that an individual member of the family
targets a single gene but they fail to study the specific miRNA in context of the family.
Furthermore, many microRNA studies focus solely on predicted targets. While this
approach is not incorrect, it does severely limit the scope of study of these microRNAs.
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Using CLASH we identified many genes to be valid targets with both CLASH and
RNA-seq support. A large number of these genes were members of the same pathway
showing that the microRNA-148/152 family targets multiple genes along the EGFR
and TGF signaling cascades. While CLASH and RNA-seq do provide strong evidence
for real targets of these miRNAs, we plan to take these genes and perform further
validation using a high-throughput GFP-reporter library. In this library, target sites
obtained from CLASH will be fused to the 3’-UTR of the GFP reporter gene. These
reporter vectors will be infected into target cells and the cells subsequently treated
with mimics of the microRNA-148/152 family. The cells would then be sorted for
GFP expression followed by sequencing of the reporter vectors to identify target sites
which resulted in effective reduction of GFP translation. This would provide the last
set of evidence for high-confidence target sites for this miRNA family and could unlock
important information about how the miRNA families co-ordinate their regulation of
targets genes. It could also answer the question of miR-152/COPZ2 specific silencing
during cancer progression as well.
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Appendix A
Code for shRNA screening analysis
#####################################################################
# shRNA_Screening_Analysis function normalizes and converts a
# count matrix into a format that LREstimates function can handle.


















dat1 <- as.matrix(read.csv(dat1, row.names = 1))









dat1[which(dat1 < thresh)] <- NA











dat1$x <- rep(1:passages, each = dim(dat1)[1]/passages)
dat2$x <- rep(1:passages, each = dim(dat2)[1]/passages)
colnames(dat1)[3] <- "y"
colnames(dat2)[3] <- "y"
bc1 <- boxcox(dat1$y~dat1$x, plotit = F)





gene.vector <- read.table(file = genes, stringsAsFactors = F)
gene.vector <- gene.vector[,1]
return.data <- NULL
for(i in 1:length(gene.vector)) {
dat1.gene <- dat1[grep(gene.vector[i], dat1$Var1),3:4]
















# BootPValue function performs a residual resampling bootstrap
# method to generate a p-value for the observed LRT inherited from
# the LikRatio function


















for (m in 1:BootRep) {
resstar1 = sample(allresids,n1)
resstar2 = sample(allresids,n2)
y1star = b10res + b11res*d1$x + resstar1
y2star = b20res + b21res*d2$x + resstar2
dat1star = data.frame(x = d1$x, y = y1star)
dat2star = data.frame(x = d2$x,y = y2star)
outstar = LikRatio(dat1star, dat2star)
BootVals[m] = outstar$NegLogLR
}








# LikRatio function calculates the LRT statistic for the observed
# data. It inherits the estimates for the linear model parameters
# from the LREstimates function






















rat1 = out1$SXX/(out1$SXX + out2$SXX)
rat2 = 1 - rat1
if(is.na((b11 < 0) && (b21 > 0) && (b21 < abs(b11)))
& is.na((b11 < 0) && (b21 < 0) && (b21 > b11))){
## catches cases where slope parameters cannot be calculated
}
else if((b11 < 0) && (b21 > 0) && (b21 < abs(b11))) {




else if((b11 < 0) && (b21 < 0) && (b21 > b11)) {




b10res = y1bar - b11res*x1bar
b20res = y2bar - b21res*x2bar
sig2hatres = (sum((d1$y - (b10res + b11res*d1$x))^2) +
sum((d2$y - (b20res + b21res*d2$x))^2))/(n1 + n2)
NegLogLR = (n1 + n2)*(log(sig2hatres) - log(sig2hat))
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if (NegLogLR < 1e-10 | is.na(NegLogLR)){
# catches errors where LR for some genes outside
# the region of interest are calculated to be
# ~ 5e-14 (almost always this value...)
NegLogLR <- 0
}

















# LREstimates calculates the estimates for the linear regression
# given a set of data.
124






SXX = (n - 1)*var(x)
SYY = (n - 1)*var(y)
SXY = (n - 1)*cov(x, y)
b1 = SXY/SXX
b0 = bary - b1*barx













Code and protocol for CLASH
Protocol for modified CLASH procedure
1. UV-Crosslinking
a) Prepare >15 p150 plates at 70 - 90% confluence
b) Thoroughly aspirate media
c) Rinse 1x with ice-cold PBS and thoroughly aspirate
d) Transfer plate to Stratalinker (keep on ice in Stratalinker)
e) Remove plate cover and Irradiate once at 4000 uJ/cm2
f) Rotate plate
g) Irradiate a second time at 2000 uJ/cm2
h) Scrape cells into 2 ml Eppy
i) Spin at 300 x g and 4oC for 4 min
j) Pour off supernatant
k) Flash-freeze in liquid nitrogen
l) Store at -80oC until ready to use.
2. Immunoprecipitation (Day 1: ≈ 6 hrs)
a) Ultracentrifugation
i. Pre-chill centrifuge, rotor, and tubes to 4oC
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ii. Thaw samples on ice
iii. Re-suspend samples in 150 ul of PXL buffer + Protease inhibitor
iv. Add 55 ul RQ1 DNase and 9 ul 1:10,000 dilution RNase (make dilution
in PXL buffer + protease inhibitor). Incubate at 37oC for 10min at
1000rpm
v. Quench RNase reaction with 15 ul RNasin Plus
vi. Merge lysate tubes into a single tube. Save 250 ul pre-IP sample.
vii. Transfer sample to clean, pre-chilled ultracentrifuge tubes
viii. Spin samples in pre-chilled ultracentrifuge at 4oC for 30min at 32,000g
ix. During centrifugation, prepare Dynabeads for IP
b) Prepare Dynabeads
i. Re-suspend the Dynabeads Protein G thoroughly to obtain a homo-
geneous suspension
ii. Transfer 750 ul of Dynabeads Protein G (30 ug/ul) to a 2 ml eppy at
room temperature
iii. Place Dynabeads on magnet for 1 min and discard the supernatant
iv. Wash with 1 ml of NaP buffer by gently inverting. Repeat 3 times
v. Remove last wash and resuspend beads in 1 ml NaP buffer
vi. Add 150 ul ( 225 ug) of 11A9 anti-AGO2 antibody or no antibody for
IgG control
vii. Rotate tubes end-over-end at room temperature for ≈ 40 min
viii. Wash antibody hybridized beads 1x with NaP buffer and 3x with PXL
buffer
c) Immunoprecipitation
i. Carefully collect supernatant from centrifuged samples
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ii. Add sample supernatant to prepped Dynabeads and mix end-over-end
at 4oC for ≈ 4 hrs
iii. Wash beads with 2x PXL, 2x HP-PXL, and 2x with PNK.
iv. To final PNK wash add 1 ul of RNAsin plus and store at 4oC until
next step (next day).
3. Intermolecular ligation (Day 2: ≈ 1.5 hrs)
a) RNA 5’ end phosphorylation
i. Prepare PNK reaction mixture
Reagent Volume (µl)
10x PNK buffer 121
10mM ATP 15
RNasin 15
T4 PNK Enzyme 60
ddH2O 1012
Total 1223
ii. Add 1200 ul of PNK reaction mixture to IP samples
iii. Incubate at 37oC for 20 min at 1000 rpm
iv. Wash 1x with ice-cold PXL buffer, 1x with ice-cold HP-PXL buffer,
and 2x with ice-cold PNK buffer
v. Store at 4oC in PNK biffer + 1ul RNAsin until next step
b) Intermolecular ligation
i. Prepare ligation reaction mixture
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Reagent Volume (µl)




T4 RNA ligase 1 60
PNK buffer 775
Total 1213
ii. Add 1200 ul of ligation reaction mixture to IP sample
iii. Incubate at 16oC overnight at 1000 rpm
iv. Next day, wash beads 1x PXL buffer and 2x with PNK buffer
4. RNA cleanup (Day 3: ≈ 4 hrs)
a) RNA dephosphorylation
i. Prepare dephosphorylation reaction mixture
Reagent Volume (µl)





ii. Add 1200 ul of dephosphorylation reaction mixture to IP sample and
incubate at 37oC for 20 min at 1000 rpm
iii. Wash beads 1x with PNK buffer, 1x with PNK+EGTA buffer, and 2x
with PNK buffer
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b) Proteinase K digestion
i. Prepare Proteinase K reaction mixture
Reagent Volume (µl)
5x Proteinase K buffer 260
10% SDS 65
RNasin 15
Proteinase K (9ug/ul) 30
ddH2O 965
Total 1335
ii. Add 1300 ul of Proteinase K reaction mixture to the IP samples
iii. Incubate at 37oC for 2 hrs with at 1000 rpm
c) RNA isolation (Zymo Research, Quick-RNA MicroPrep, R1050)
i. Perform RNA isolation according to the manufacturer’s protocol in-
cluding on-column DNase treatment.
d) Store at -80oC until sequencing library preparation
5. RNA quantification (ThermoFisher Scientific, Quant-iT RiboGreen RNA Assay
Kit, R11490) (Day 4: 1.5hrs)









































f) 5x Proteinase K buffer:
Reagent Volume (ml)





Code for CLASH sequencing data processing
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#!/bin/bash
# pass two arguments to this script
# arg[0] is the destination directory for all analysis files.
# arg[1] is the location of the sequencing fastq files
# this program requires the following scripts to be in the PATH
# fastx_barcode_splitter.pl, STAR, AND Re_pair_reads.py
if [ "$#" -ne 2 ]; then
printf "Incorrect number of parameters\n \
Usage: Alt_Clash_Pipe.sh <New Directory Name> \
<Location of Sequencing Data>\n"
exit 2
fi
if hash fastx_barcode_splitter.pl 2>/dev/null; then
echo "Found fastx_barcode_splitter.pl in the PATH...continuing"
else




if hash Re_pair_reads.py 2>/dev/null; then
echo "Found Re_pair_reads.py in the PATH...coninuing"
else





if hash STAR 2>/dev/null; then
echo "Found STAR-aligner in PATH."
else






if [ -d $TOPDIR ]; then
cd $TOPDIR
else





### Download the human genome hg38 for aligning reads
if [ -d "Genome" ]; then
echo "Genome dir already exists."
GENOMEFILES=‘ls -1 $TOPDIR/Genome/*.fa* 2>/dev/null | wc -l‘
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if [ $GENOMEFILES -ne 0 ]; then
echo "Found file that looks like a genome fasta. \
Not retrieving genome."
else
echo "No genome files found. Retrieving genome from UCSC. \







echo "Making Genome dir."
echo "No genome files found. Retrieving genome from UCSC. \








### Generate miRNA "barcodes" from miRBase’s list of HC miRNAs
if [ -d "BarCodes" ]; then
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echo "Barcodes dir already exists."
BARCODEFILES=‘ls -1 $TOPDIR/BarCodes/*.fa* 2>/dev/null | wc -l‘
if [ $BARCODEFILES -ne 0 ]; then
echo "Found file that looks like microRNA fasta file. \
Not retrieving sequences."
else
echo "No microRNA fasta files found. \





echo "Making BarCodes dir."
mkdir $TOPDIR/BarCodes
cd $TOPDIR/BarCodes/




if [ -s All_HC_barcodes_Uniq.txt ]; then
echo "Barcode file already generated, skipping to next step."
else
echo "Generating Barcodes from mature microRNA sequences."
zcat high_conf_mature.fa.gz | grep -A 1 ’^>hsa*’ | \
cut -d’ ’ -f1 | \
grep -E ’^>|’^[ACUG]’’ > All_HC_barcodes.txt
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sed -i ’s/U/T/g’ All_HC_barcodes.txt
sed -i ’s/-/_/g’ All_HC_barcodes.txt
grep ’^>’ All_HC_barcodes.txt > temp1.txt
grep ’[ACTG]’ All_HC_barcodes.txt | cut -c1-20 > temp2.txt
paste temp1.txt temp2.txt > All_HC_barcodes.txt
sed -i ’s/>//g’ All_HC_barcodes.txt
SHORTMIRNA=$(grep -n ’ACGTTGGCTCTGGTGGTG’ All_HC_barcodes.txt | \
cut -d : -f 1)
sed -ie "${SHORTMIRNA}d" All_HC_barcodes.txt
sort -u -k 2,2 All_HC_barcodes.txt > All_HC_barcodes_Uniq.txt
rm *temp*
fi
if [ -s All_HC_barcodes_Uniq_RC.txt ]; then
echo "Reverse compliment barcodes also found, \
skipping to next step."
else
cat All_HC_barcodes_Uniq.txt | tr ACTG TGAC | \
cut -d$’\t’ -f2 | rev | \
paste -d ’\t’ <(cat All_HC_barcodes_Uniq.txt | \




### Split FASTQ files by their miRNA using FASTX barcode splitter
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TESTEMPTY=‘ls -1 $TOPDIR/Split/* 2>/dev/null | wc -l‘
SEQFILES=‘ls -1 $SEQDIR/* 2>/dev/null | wc -l‘
if [ ! -d $SEQDIR ]; then
echo "Directory containing sequencing data -- $SEQDIR \
-- does not exist"
exit 1
elif [ $SEQFILES -eq 0 ]; then
echo "Sequencing directory does not contain fastq files"
exit 1
else
if [ ! -d "$TOPDIR/Split" ]; then
echo "Directory for split fastqs does not exist. Creating it."
mkdir $TOPDIR/Split
cd $SEQDIR
TESTGZ=‘ls -1 $SEQDIR/*.gz 2>/dev/null | wc -l‘
TESTFQ=‘ls -1 $SEQDIR/*.fastq 2>/dev/null | wc -l‘
if [ $TESTGZ -ne 0 ]; then
echo "Fastq Files are gzipped."
READ1FILES=($(ls *_R1_*.gz))
COUNTER=0
while [ $COUNTER -lt ${#READ1FILES[@]} ]; do
echo "Running FastX barcode splitting...$COUNTER"







elif [ $TESTFQ -ne 0 ]; then




while [ $COUNTER -lt ${#READ1FILES[@]} ]; do







echo "Could not detect file type for barcode splitting"
exit 2
fi
elif [ $TESTEMPTY -eq 0 ]; then




if [ -s $TESTGZ ]; then




while [ $COUNTER -lt ${#READ1FILES[@]} ]; do
echo "Running FastX barcode splitting...$COUNTER"






elif [ $TESTFQ -ne 0 ]; then
echo "Fastq files detected"
READ1FILES=($(ls *_R1_*.fastq))
COUNTER=0
while [ $COUNTER -lt ${#READ1FILES[@]} ]; do


















### Calculate number of reads containing each miRNA per sample
cd $TOPDIR/Split/
find $TOPDIR/Split/ -type f -size 0 -delete
COUNTER=0
READFILESIN=($(ls))
while [ $COUNTER -lt ${#READFILESIN[@]} ]; do
COUNTS=‘expr $(wc -l ${READFILESIN[$COUNTER]} | cut -f1 -d’ ’) / 4‘
NAMES=‘wc -l ${READFILESIN[$COUNTER]} | cut -f2 -d’ ’‘
echo $COUNTS $NAMES >> $TOPDIR/count_summary.txt
let COUNTER=COUNTER+1
done
TESTFQ=‘ls -1 $TOPDIR/Split/*.fastq 2>/dev/null | wc -l‘
if [ $TESTFQ == 0 ]; then







### Trim the microRNA from the reads to align associated mRNA
TESTEMPTY=‘ls -1 $TOPDIR/Trimmed/* 2>/dev/null | wc -l‘
if [ ! -d $TOPDIR/Trimmed ]; then
echo "Making a fresh dir to place trimmed reads in..."
mkdir $TOPDIR/Trimmed
cd $TOPDIR/Trimmed
for MIRS in ‘seq $(cat $TOPDIR/BarCodes/All_HC_barcodes_Uniq.txt | \
wc -l)‘; do
for FILES in $(find $TOPDIR/Split/ -name "*_$(sed "${MIRS}q;d" \
$TOPDIR/BarCodes/All_HC_barcodes_Uniq.txt | \
cut -d$’\t’ -f1)*"); do
cutadapt -g "$(sed "${MIRS}q;d" \
$TOPDIR/BarCodes/All_HC_barcodes_Uniq.txt | \
cut -d$’\t’ -f2)" -o ‘basename $FILES‘ $FILES
done
done
elif [ $TESTEMPTY -eq 0 ]; then
cd $TOPDIR/Trimmed
for MIRS in ‘seq $(cat $TOPDIR/BarCodes/All_HC_barcodes_Uniq.txt | \
wc -l)‘; do
for FILES in $(find $TOPDIR/Split/ -name "*_$(sed "${MIRS}q;d" \
$TOPDIR/BarCodes/All_HC_barcodes_Uniq.txt | \
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cut -d$’\t’ -f1)*"); do
cutadapt -g "$(sed "${MIRS}q;d" \
$TOPDIR/BarCodes/All_HC_barcodes_Uniq.txt | \








### Trim the sequencing adapters from the 5’ and 3’ end of the read
TESTEMPTY=‘ls -1 $TOPDIR/Processed/* 2>/dev/null | wc -l‘
if [ ! -d $TOPDIR/Processed ]; then
echo "Making a fresh dir to place processed reads in..."
mkdir $TOPDIR/Processed
cd $TOPDIR/Processed
for FILES in $(find $TOPDIR/Trimmed/); do
cutadapt -b AGATCGGAAGAGCACACGTCT \
-m 30 \
-o ‘basename $FILES‘ $FILES
done
elif [ $TESTEMPTY -eq 0 ]; then
cd $TOPDIR/Processed
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for FILES in $(find $TOPDIR/Trimmed/); do
cutadapt -b AGATCGGAAGAGCACACGTCT \
-m 30 \
-o ‘basename $FILES‘ $FILES
done
else
echo "Processed reads detected, skipping to next step..."
fi
find $TOPDIR/Processed/ -size 0 -delete
cd $TOPDIR
#####################################################################
### Some reads are lost during adapter trimming so the paired reads
### need to be re-ordered before passing them to the aligner
ln -s $(which Re_pair_reads.py) $TOPDIR/
TESTEMPTY=‘ls -1 $TOPDIR/Re_Paired/* 2>/dev/null | wc -l‘
if [ ! -d $TOPDIR/Re_Paired ]; then
echo "Making a fresh dir to place re-paired reads in..."
mkdir $TOPDIR/Re_Paired
cd $TOPDIR/Re_Paired
TESTGZ=‘ls -1 $SEQDIR/*.gz 2>/dev/null | wc -l‘
TESTFQ=‘ls -1 $SEQDIR/*.fastq 2>/dev/null | wc -l‘
if [ $TESTFQ -ne 0 ]; then
for TRIMMED in $(find $TOPDIR/Processed/ -name "*_R1_*"); do
for SECOND in $(find $SEQDIR/ -name "*_R2_*.fastq"); do
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TMP=‘basename $TRIMMED‘
python $TOPDIR/Re_pair_reads.py $TRIMMED $SECOND ${TMP%.*}
done
done
elif [ $TESTGZ -ne 0 ]; then
for GZIPPED in $(find $SEQDIR/ -name "*_R2_*.gz"); do
gunzip $GZIPPED
done
for TRIMMED in $(find $TOPDIR/Processed/ -name "*_R1_*"); do
for SECOND in $(find $SEQDIR/ -name "*_R2_*.fastq"); do
TMP=‘basename $TRIMMED‘




echo "Could not detect files for re-pairing reads"
fi
elif [ $TESTEMPTY -eq 0 ]; then
cd $TOPDIR/Re_Paired
TESTGZ=‘ls -1 $SEQDIR/*.gz 2>/dev/null | wc -l‘
TESTFQ=‘ls -1 $SEQDIR/*.fastq 2>/dev/null | wc -l‘
if [ $TESTFQ -ne 0 ]; then
for TRIMMED in $(find $TOPDIR/Processed/ -name "*_R1_*"); do
for SECOND in $(find $SEQDIR/ -name "*_R2_*.fastq"); do
TMP=‘basename $TRIMMED‘




elif [ $TESTGZ -ne 0 ]; then
for GZIPPED in $(find $SEQDIR/ -name "*_R2_*.gz"); do
gunzip $GZIPPED
done
for TRIMMED in $(find $TOPDIR/Processed/ -name "*_R1_*"); do
for SECOND in $(find $SEQDIR/ -name "*_R2_*.fastq"); do
TMP=‘basename $TRIMMED‘




echo "Could not detect files for re-pairing reads"
fi
else
echo "Re-paired reads detected. Skipping to next step."
fi




### Align reads to the genom with STAR aligner
TESTGENOME=‘ls -1 $GENOMEDIR/Genome 2>/dev/null | wc -l‘
if [ $TESTGENOME -eq 0 ]; then
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echo "STAR genome not yet generated. \
Generating STAR indexed genome now..."
TESTGZ=‘ls -1 $GENOMEDIR/*.gz 2>/dev/null | wc -l‘
TESTEMPTY=‘ls -1 $GENOMDIR/* 2>/dev/null | wc -l‘
if [ $TESTEMPTY -eq 0 ]; then
echo "no files detected...\
this should never happen because of step 1..."
elif [ $TESTEMPTY -ne 0 -a $TESTGZ -eq 0 ]; then
echo "building genome..."




elif [ $TESTEMPTY -ne 0 -a $TESTGZ -ne 0 ]; then
echo "Unzipping genome file for STAR index build..."
for GZIPPED in $(find $GENOMEDIR/ -name "*.gz"); do
gunzip $GZIPPED
done










echo "STAR genome detected, aligning reads..."
fi
TESTEMPTY=‘ls -1 $TOPDIR/Aligned/* 2>/dev/null | wc -l‘
if [ ! -d $TOPDIR/Aligned ]; then
echo "Making a fresh dir to place Aligned reads in..."
mkdir $TOPDIR/Aligned
cd $TOPDIR/Aligned
for INREAD in $(find $TOPDIR/Re_Paired/ -name "*Read1.fastq"); do
INREADBASE=‘basename $INREAD‘




--readFilesIn $INREAD ${INREAD/Read1/Read2} \
--outFileNamePrefix ${INREADBASE%_*}_
done
elif [ $TESTEMPTY -eq 0 ]; then
cd $TOPDIR/Aligned
for INREAD in $(find $TOPDIR/Re_Paired/ -name "*Read1.fastq"); do
INREADBASE=‘basename $INREAD‘









echo "Files already aligned. exiting."
exit 0
fi
cd $TOPDIR
exit 0
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